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ABSTRACT
Parkinson’s disease is the second most common neurodegenerative disorder. It is
characterized by the death of dopaminergic neurons in the substantia nigra and a series of
debilitating motor symptoms. Macroautophagy (hereafter referred to as autophagy) is a
cellular process by which cells degrade proteins, lipids, organelles or dysfunctional
components. Autophagy is thought to play an important role in Parkinson’s disease,
because it is the only cellular process known to remove large protein aggregates, such as
those seen in Parkinson’s disease pathology. Historically, a large body of work has
focused on reporting on protein effectors of autophagy, and regulation of autophagy but
lipophilic molecules has garnered less attention. This dissertation focuses on the
regulatory contributions of lipid molecules to autophagy in addition to describing the
identification and lead discovery of autophagy-regulating lipid factors using an
endogenous lipid chaperone protein, known as Fatty Acid Binding Protein 5, as a ‘bait’
molecule.
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CHAPTER ONE: A REVIEW OF SIGNALING AND OTHER ROLES OF LIPIDS IN
AUTOPHAGY
The process of autophagy is integral to cellular function. In this process, proteins,
organelles, and metabolites are engulfed in a lipid vesicle and trafficked to a lysosome for
degradation. Its central role in protein and organelle homeostasis has piqued interest for
autophagy dysfunction as a driver of pathology for a number of diseases including
cancer, muscular disorders, neurological disorders, and non-alcoholic fatty liver disease.
For much of its history, the study of autophagy has centered around proteins, however,
due to advances in mass spectrometry and refined methodologies, the role of lipids in this
essential cellular process has become more apparent. This review discusses the diverse
endogenous lipid compounds shown to mediate autophagy. Downstream lipid signaling
pathways are also reviewed in the context of autophagy regulation. Specific focus is
placed upon the Mammalian Target of Rapamycin (mTOR) and Peroxisome Proliferator
Activated Receptor (PPAR) signaling pathways as integration hubs for lipid regulation of
autophagy.
Introduction
Autophagy is a process by which proteins, organelles, and metabolites are broken
down and turned over often as a response to starvation or as a means to protect the cell
from damage. Autophagy pathways come in three forms, macroautophagy,
microautophagy, and chaperone-mediated autophagy 1. Of these, macroautophagy is the
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best characterized and most well understood. Macroautophagy (hereafter referred to as
autophagy) was originally studied in yeast and involves the formation of lipid vesicles
known as autophagosomes that engulf cargo to be degraded. Once formed, the
autophagosome is trafficked to a lysosome and a fusion event occurs resulting in the
degradation of the cargo within the autophagosome (Figure 1.1) 1.
Autophagy is delineated into key events: initiation, nucleation, elongation, and
formation of a mature autophagosome, fusion of the autophagosome with a

Figure 1.1
Autophagy mechanism. Autophagy is a cellular mechanism by which
metabolites, organelles, proteins, and protein aggregates are enveloped by a
vesicular membrane to form an autophagosome. The autophagosome is trafficked to
a lysosome where fusion occurs, and lysosomal degradative enzymes break down the
cargo.
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lysosome, and degradation of cargo. Initiation of autophagy is tightly regulated by the
mTOR complex 1 2. When the cell is in a nutrient-rich state, mTORC1 is active and
autophagy is suppressed, however during nutrient-poor conditions, mTOR is inhibited
which allows for the formation of Unc-51 like kinase (ULK) initiation complex
composed of ULK kinases, autophagy related protein 13 (Atg13), Autophagy related
protein 101 (Atg101), and RB1-inducable coiled-coil protein 1 (FIP200) 3. Furthermore,
ULK-1 also activates a second complex composed of Beclin1-vacuolar protein sorting
protein 34 (VPS34)-autophagy related protein 14 (Atg14L)-P150, which produces
phosphatidylinositol-3-phosphate (PI3P) (Figure 1.1) 4. This complex is responsible for
autophagic vesicles budding from the endoplasmic reticulum and forming a structure
known as an omegasome. In mammals this is the site responsible for the nucleation of
autophagosomes 5. Next, phosphatidylethanolamine (PE) is conjugated to microtubule
associated light protein light chain 3 (LC3) by autophagy related protein 7 (Atg7) and
autophagy related protein 3 (Atg3), which are ubiquitin-like conjugating enzymes. Then
the conjugated PE-LC3 is inserted into the autophagosome membrane 6. In addition,
autophagy related protein 12 (Atg12) is conjugated to autophagy related protein 5 (Atg5)
by Atg7 and autophagy related protein 10 (Atg10) also in a ubiquitin like manner 7.
Atg12-Atg5 interacts with autophagy related 16 like protein (Atg16L) and promotes
elongation 8. Meanwhile cargo is selected by ubiquitination and interaction with cargo
receptor proteins p62/ sequestome 1 (sqstm1). Cargo bound to p62 then binds to the p62
interacting regions of LC3 9. After the cargo is selected, the autophagosome matures by
disassembling the autophagy related proteins from the outer layer with the help of
myotubularin 3 (MTMR3), a PI3P phosphatase 10. Once matured, the autophagosome will
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fuse with early and late endosomes as well as with lysosomes this is mediated by
Rubicon, UV resistance-associated gene (UVRAG), Ras related protein 7 (Rab7), snap
receptor proteins (SNAREs), and Lysosome-associated membrane glycoproteins
(LAMPs) 11-13. Once fusion with a lysosome is complete, the cargo is degraded. In
mammals, lysosomal hydrolases break down cargo. Beneficial components, such as
amino acids are then returned to the cytosol via amino acid effluxers such as vacuolar
amino acid transporter 3 (Avt3) and vacuolar amino acid transporter 4 (Avt4) 14.
Lipid Signaling Directs Autophagy
While autophagy has been studied extensively through the years, the role of
lipids in this process is underrepresented. Historically, working with lipids has presented
a challenge, leading to emphasis on work that primarily focused upon protein
contributions. However, recent advances in both mass spectrometry capabilities and
methodologies have spurred considerable progress in the study of lipids. For example,
lipophagy, the targeted breakdown of lipid droplets by autophagic pathways, is currently
being studied in the context of non-alcoholic fatty liver disease, aging, and cancer. It is
becoming more apparent that lipids play a prominent role in autophagy. mTOR, the
master regulator of cell growth, metabolism, and autophagy is itself a part of a signaling
cascade in which lipid phosphoinositides are involved. In addition, Peroxisome
Proliferator-activating factors (PPARs), are nuclear receptors which respond to lipid
signals and have been implicated in the control of autophagy and autophagy related
genes. For all of these reasons, this review seeks to provide a comprehensive overview of
the growing field of lipid signaling. In the subsequent sections of this article, we discuss
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the different lipid signaling pathways known to regulate autophagy and their implications
in disease states.
Impaired Autophagy in Human Disease
Autophagy is of considerable interest as a potential target for treatment in many
diseases that include cancer, muscular disorders, and neurodegenerative disease. The
fundamental role for organelle, particularly mitochondria, and biomolecule turnover by
autophagy provides a broad influence of this process in cellular physiology. In addition,
autophagy is the only known cellular process for removing protein aggregates making
study of this process of considerable interest in protein aggregation disorders which
coincide with numerous neurodegenerative diseases. Therefore, understanding and
developing tools to manipulate autophagy could yield widespread therapeutic benefits.
Due to its regulation by mammalian target of rapamycin (mTOR), autophagy is
intimately involved in growth, cell death and cytoprotective processes. As a result, there
is great interest in harnessing this process in the context of cancer. In early stages,
suppression of autophagy is believed to facilitate the uncontrolled growth 15. In later
stages, cells may require increased autophagy in low-oxygen and low-nutrient conditions,
such as those seen in tumors 16. Autophagy also can protect tumors from ionizing
radiation by helping to remove damaged organelles and proteins 17. Dysfunction in the
phosphatidylinositol-3-kinase (PI3K)-protein kinase B (Akt)-mTOR pathway has been
commonly seen to result in altered autophagy. This pathway, when active, suppresses
autophagy and uses lipid signaling molecules such as phosphatidylinositol-3,4,5triphosphate (PIP3) as key signal transducers 18. Mutations in phosphatase and tensin
homolog (PTEN), a phosphatase that antagonizes PI3K and causes positive regulation of
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autophagy, result in aberrant inhibition of autophagy that has been associated with
excessive growth and tumor formation 19. Another common mutation in cancers that
leads to autophagy dysfunction is Beclin-1. A high percentage of human breast, ovarian,
and prostate cancers have a heterozygous mutation in this gene. Beclin-1 is a part of the
initiation complex responsible for activating lipid kinases required for the formation of
autophagosomes. In breast carcinoma cell line MCF7, it has been established that Beclin1 expression is below detectable limits, and transfection of the Beclin-1 gene upregulates
autophagy 15. Studies have also shown that mice with a heterozygous deletion of Beclin-1
are more susceptible to developing tumors 20, 21. This is further evidence of the role of
beclin-1 and autophagy play in cancer.
Autophagy has also been implicated in muscular disorders. It is common for
autophagy to play an important role in post-mitotic cells, such as muscle cells and
neurons due to the potential for damage from accumulation of dysfunctional or toxic
molecules, protein or organelles. Vacuolar myopathy is a type of muscular disease in
which the structure of lysosomes is abnormal either from a deficiency in lysosomal

7

Figure 1.2
PI3K-mTOR autophagy pathway utilizes PIP3 lipid signaling. PI3K
converts the lipid PIP2 to PIP3. PIP3 mediates the phosphorylation of PDK1
causing the activation of AKT. AKT inhibits the activation of the TSC1/2 complex
by phosphorylating TSC2. The inhibition of the TSC1/2 complex results in
inhibition of Rheb GTPase which in turn activates mTORC1. MTORC1 inhibits the
activation of the ULK activation complex leading to an inhibition of autophagy.
Inversely, phosphatase activity of PTEN converts PIP3 to PIP2 which suppresses the
activation of PDK1 and downstream AKT. Inhibited AKT cannot suppress the
TSC1/2 complex allowing Rheb GTPase to remain active. An active Rheb results in
inhibition of mTORC1 and an activation of the ULK1 complex
enzymes or a deficiency in lysosomal membrane proteins 22. Therefore, it is not
surprising that diseases in which lysosomal function is affected also result in the altered
autophagy. In fact, an accumulation of autophagosomes is typically required to diagnose
vacuolar myopathies 23. In addition, an autophagy related gene has been associated with a
vacuolar myopathy known as Danon’s disease. In Danon’s disease, mutations in
lysosome associated membrane protein 2 (LAMP-2) have been identified 23. LAMP-2 is a
lysosomal membrane protein whose function is still not fully understood. However,
studies in which the Lamp2 gene is deleted in mice result in a Danon’s disease-like
phenotype and an accumulation of autophagosomes 23.
Autophagy has long been thought to play an important role in neurodegenerative
disorders. A prominent hallmark of these diseases is the accumulation of protein
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aggregates associated with neuronal loss in the brain. Noted examples include: ɑSynuclein Lewy bodies in Parkinson’s disease, Tau neurofibrillary tangles in Alzheimer’s
disease, Superoxide dismutase 1 (SOD1)-mediated aggregates in Amyotrophic Lateral
Sclerosis, and mutant Huntingtin protein aggregates in Huntington’s disease 24-28. It is
speculated that these aggregates may be substrates for autophagy, and that in these
disease states, autophagy is disrupted. Several proteins have been identified and are
linked to dysfunction in various steps of autophagy in each of these diseases. For
example, in Alzheimer’s disease, autophagy induction is disrupted by reduced expression
of Beclin-129. In Parkinson’s disease, an overexpression of ɑ-Synuclein causes the
inhibition of GTPase Rab1. This inhibition is responsible for the mislocalization of
autophagy related protein 9 (Atg9), a protein involved in the formation of
autophagosomes 30. Also, PTEN induced kinase 1(PINK1) and Parkin are proteins
involved in the recognition of damaged mitochondria normally targeted for degradation
mitophagy. Loss of function mutations in these proteins can prevent the necessary
destruction of damaged mitochondria through autophagy resulting in cell death 31,32. In
addition, the park9 gene encodes lysosomal type 5 p-type ATPase (ATP13A2).
Autosomal recessive mutations in the park9 gene result in levodopa-responsive earlyonset Parkinson's Disease. This loss of function mutation is responsible for aberrant
expression of zinc transporters and an impairment in the ability for Zn 2+ to enter
lysosomal vesicles resulting in an induction of reactive oxygen species and impairment of
mitochondrial function 33. In Huntington’s disease, mutant huntingtin protein is known to
affect several stages in autophagy 32. Many research groups have reported changes in
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expression of mRNA corresponding to genes in the autophagic pathway 34. In addition, a
polymorphism in the ATG7 gene has been linked to early onset Huntington’s isease 35.
Phospholipids, Sphingolipids, and mTOR Signaling
Phosphoinositides are a class of phospholipids derived from phosphatidylinositol,
which is found in the inner layer of the cell membrane and are commonly used by the cell
as signaling molecules 36. They play a major role in the regulation of autophagy through
phosphorylation and dephosphorylation at the 3,4 and 5-hydroxyl positions of the inositol
ring. They control the pathway that directly regulates mTOR 37. mTOR itself is a master
regulator of growth, anabolic processes, and autophagy. Generally, mTOR is activated in
response to insulin, other nutrients such as amino acids or triglycerides, and growth
factors. When active, mTOR promotes growth and suppresses autophagy. In response to
starvation, the cell inhibits mTOR and autophagy is promoted 2.
The canonical signaling pathway that controls autophagy functions through PIP3.
The pathway begins as a response to insulin, other nutrients, or growth factors 38.
Phosphoinositide 3-kinases convert phosphatidylinositol 4,5- bisphosphate (PIP2) to PIP3.
PIP3 activates phosphoinositide dependent kinase-1 (PDK1) which in turn phosphorylates
Akt 39,40. Akt then phosphorylates tuberous sclerosis 2 (TSC2) which results in the
inhibition of the tuberous sclerosis 1/2 (TSC1/2) complex 41. When inhibited, TSC1/2
cannot activate Rheb GTPase activity permitting activation of mTOR. When bound to
GTP, Rheb mediates the activation of mTOR complex 1 (mTORC1) which, in turn,
inhibits autophagy 42. Activated mTORC1 inhibits autophagy by inhibiting the ULK1
initiation complex. Pro-autophagy signals result in ULK1 dissociation from mTOR and
autophagy initiation is facilitated (Figure 1.2) 43.

10
PI3P also plays an integral role in the process of autophagy by interacting with
VPS34 44. Originally identified and studied in yeast, VPS34 is a class III
phosphatidylinositol 3 kinase. In yeast, VPS34 forms one of two complexes. VPS34
complex-I is composed of VPS34, VPS30/ATG6, VPS15, and ATG14 and is implicated
in the initiation of the pre-autophagosomal structure (PAS) 45,46. In Mammals, VPS34 is
thought to play a similar role in autophagy initiation. However, it has been difficult to
study in mouse models since pan knockouts of VPS34 are embryonically lethal, and there
are no inhibitors specific to VPS34 necessitating the use of low specificity inhibitors,
such as wortmannin or 3-MA 47. Conditional knockout studies using cultured mice
embryonic fibroblasts have shown that VPS34 is required for the formation of
autophagosomes 48. In addition, VPS34 is involved with mTOR regulation of autophagy.
Studies using mice embryonic fibroblasts have shown that mTORC1 must be inactivated
for the VPS34 initiation complex to be active and that mTORC1 is able to inhibit the
phosphatidylinositol 3-kinase activity of this complex by phosphorylating ATG14 48.
PI3P is also a component of the autophagosome. It has been observed to be enriched in
the concave surface of early phagophores 49. Because of this, PI3P is thought to facilitate
the expansion and sealing of autophagosomes.
In addition to its function in the autophagosomal membrane, PI3P is thought to
mediate selected cargo capture via its interaction with autophagy linked FYVE protein
(Alfy), a nuclear scaffold protein with a FYVE domain that binds PI3P 50. In the
autophagic process, Alfy interacts with Ath5 and P62 through its WD40 domain and with
PI3P through its FYVE domain. The high amount of PI3P in the inner membrane of
autophagosomes is believed to act as a dock for this Alfy/Atg5/P62 complex in the
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selective engulfment of protein aggregates that results in aggregate clearance known as
aggrephagy 51.
Metabolites formed from the breakdown of phospholipids are also involved in
autophagy. Phosphatidic acid is formed by the breakdown of phosphatidylcholine into
choline and phosphatidic acid by Phospholipase D 52. Phosphatidic acid plays a role in
autophagy by inducing membrane curvature due to its cone shape. In addition,
Phosphatidic acid is formed as a result of an absence of nutrients and serves as an
inhibitor of mTORC1 thus acting as a positive regulator of autophagy 53. Phosphatidic
acid can also be converted into diacylglycerol by the Phosphatidic Acid Phosphatases
which has other autophagy regulating properties 54. Diacylglycerol modulates autophagy
by activating Protein Kinase C which induces autophagy by disrupting the B-cell
lymphoma protein 2 (Bcl-2)-Beclin-1 complex via c-Jun N terminal kinase (JNK) and
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 54.
Sphingolipids are a class of lipids involved in several processes ranging from
apoptosis to cell proliferation to differentiation, inflammation and autophagy 55. In
autophagy two sphingolipids have been found to play sizeable roles, ceramide and
sphingosine -1-phosphate. Ceramide activates autophagy by inhibiting Akt and resulting
in an inactivation of mTOR and an upregulation of Beclin-1 function 56. Sphingosine-1phosphate is formed by the hydrolysis of ceramide into sphingosine followed by its
phosphorylation by Sphingosine Kinases 1 and 2 57. Sphingosine Kinase 1 is activated by
starvation signals and drives the formation of sphingosine-1-phosphate 57. In addition,
sphingosine kinase 1 inhibits mTORC1 independently of Akt while upregulating beclin-1
expression, ultimately promoting cell survival 57.
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Signaling Through the PPAR Family
PPARs are a family of nuclear receptor proteins that act as transcription factors.
There are 3 isoforms of PPARs in mammals, PPARα, PPARδ, and PPARγ 58. All 3
isoforms of PPARs must bind with a Retinoid Receptor X (RXR) and a lipid ligand in
order to act as transcription factors (Figure 1.3) 59. Generally, they have been reported to
bind to oleic acid, linoleic acids, linolenic acids, prostaglandins, eicosanoids, and
oxidized lipids with the help of fatty acid binding proteins which bind lipophilic ligands
in the cytoplasm and shuttle them to their target PPAR 60, 61. PPARs bind to their ligands
through the ligand binding domain (LBD). These domains consist of 12 α-helices
arranged into an ‘antiparallel helix sandwich’ and a three-stranded antiparallel β-sheet.
The ligand binding site is located in the core of the ligand binding domain that is formed
by helices 3,5,7,11, and 12. The cavity formed by these helices is T-shaped 62. In order
for ligands to bind to PPAR-α or PPAR-γ they must be able to form a U-shaped
conformation, and in order to bind to PPAR-delta ligands must form an L-shaped
conformation 63. All PPARs isoforms have been shown to modulate autophagy in the
context of different diseases and cellular responses.
PPARα is primarily expressed in the liver, brown adipose tissue, heart, and
kidney. It promotes uptake and catabolism of fatty acids by helping to express fatty acid
transport and binding genes 58 64. It has been thought to be involved in innate immune
response during mycobacterium infection 65. In studies with tuberculosis infected bone
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Figure 1.3
Overview of PPAR signaling and mechanism for PPARα-mediated
autophagy activation in innate immune system. Initially, lipid molecule enters the
cell and is quickly bound by a fatty acid binding protein. The fatty acid binding
protein transports the lipid to a PPAR which in turn activates a corresponding
RXR. The PPAR-RXR complex crosses into the nucleus and facilitate expression of
required genes. In the case of tuberculosis infection, PPARα upregulates the
expression of TFEB which, in turn, drives the expression of autophagy related
genes, LAMP3 and RAB7 thus stimulating autophagy.
derived macrophages, PPARα were shown to stimulate autophagy and autophagosomal
maturation, while suppressing inflammatory responses. It was determined that following
PPARα activation, Transcription Factor EB (TFEB) was activated and a series of
autophagy and lysosomal genes were expressed such as LAMP3 and Rab7 65. Based on
this work, it is thought that, in mycobacterial infections, such as tuberculosis, PPARα is
activated and in turn activates TFEB. Together they promote the expression of
autophagy-related genes which stimulate autophagy (Figure 1.3).
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PPAR δ has high expression levels in the colon, small intestine, liver, heart lung
and brain. It plays an important role in diseases such as diabetes, obesity, atherosclerosis,
and cancer 58,64. This is especially poignant, because there are great efforts in exploiting
autophagy as possible treatments for cancer and diabetes. Studies in mice cells have
shown a marked decrease in autophagic markers associated with the knockout of PPAR δ
suggesting its involvement in autophagy 66.

Figure 1.4
PPARγ mediated activation of autophagy. PPARγ promotes the
expression of PTEN. High amounts of PTEN lead to lower concentrations of
PI(3,4,5)P3. Less PI(3,4,5)P3 inhibits the activation of PDK1 and ultimately results
in inhibition of mTORC1 which causes an activation of autophagy.
Finally, PPARγ is expressed in adipose tissue, the intestines and macrophages. It
is usually involved in fatty acid storage, glucose uptake, and adipogenesis 58,64. Because
of its role controlling the availability of nutrients, there has been interest in targeting it as
a treatment for cancer. In Colorectal cancer, studies with Caco-2, a common colorectal
cancer cell line, have shown that activation of autophagy occurs following treatment with
PPARγ agonist rosiglitazone 67. In addition, inhibition of autophagy with 3-MA was
observed to induce expression of PPARγ. PPARγ was determined to cause the induction
of PTEN, an antagonist to PI3K which dephosphorylates and reduces the concentration of
PIP3 67. This results in an overall inhibition of the mTOR pathway and induces
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autophagy. In the context of breast cancer, PPARγ has also been implicated to modulate
autophagy. Activation of PPARγ by agonist troglitazone was shown to induce autophagy
in MDA-MB231 cells as determined by the measurement of acidic vesicular organelles
by staining with Acridine orange 68. In addition, studies of constitutively active PPARγ
suggest that it is sufficient for the activation of autophagy leading to the belief that
autophagy acts to protect cancer cells (Figure 1.4) 68.
Lipid Metabolism and Autophagy
Autophagy is intricately related to the metabolism of lipids, namely triglycerides,
due to the fact that it responds to the presence or absence of nutrients in the cell.
Furthermore, it is involved with the breakdown of stored lipids in the cell. Triglycerides
are stored in organelles known as lipid droplets. They are used to generate energy,
building blocks for membranes, and for lipid signaling 69. Lipid droplets are broken down
for use by the cell via lipophagy. This process is mediated by the GTPase Rab7 in
hepatocytes and results in the release of free fatty acids under starvation conditions to be
used as fuel in the mitochondria and undergo β-oxidation. Rab7 was shown to mediate
the docking of autophagosome to lipid droplets facilitating their catabolism 70. In
addition, Adipose triglyceride lipase (ATGL) is a regulator of lipophagy. When knocked
down in hepatocytes, ATGL causes decreased lipophagy. This ATGL signaling has been
observed to occur through sirtuin 1. Together, these two proteins drive lipophagy and
fatty acid oxidation 71.
Additionally, breakdown of lipid droplets by lipophagy can be regulated by
transcription factors. TFEB mediates the activation of PPAR alpha as a response to
nutrient deprivation in order to activate lipophagy 72 Additionally, forkhead homeobox
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protein O1 (FOXO1) becomes upregulated in nutrient restricted conditions and increases
lipophagy of lipid droplets. The FOXO1 mediated lipophagy activation is facilitated by
an increased expression of lysosomal acid lipase (LIPA) resulting in a release of free fatty
acids through adenosine monophosphate kinase (AMPK)-dependent β-oxidation in
adipocytes in nutrient restricted conditions 73.
Conversely autophagy is linked to the biosynthesis of new triglycerides as well.
Not only does autophagy drive the breakdown of lipid droplets, but it is also tied to the
metabolic balance of liver triglycerides. Diets low in protein result in a reduced
expression of autophagy receptor SQstm1 and increases the expression of LC3-II. This
correlates to an induction of autophagy. It is speculated that, in the case of low protein
availability, autophagy does not catabolize lipids and instead may help triglycerides to
accumulate in the liver 74. Additionally, Perilipin-2, a protein that associates with lipid
droplets, has been observed to protect lipid droplets from autophagy. Perilipin-2 has been
observed to inhibit lipogenesis and triglyceride production as well as upregulating
autophagy when it is depleted in the cell 75.
Free Fatty Acids and Cholesterol
Free fatty acids have also been implicated in the autophagic pathway. Although
they usually act as nutrients, fatty acids can induce cell death when they accumulate in
excessive levels in non-adipose cells and tissues. This is known as lipotoxicity and has
been observed in diseases such as obesity, diabetes, and non-alcoholic fatty liver disease
76

. As a result, levels of free fatty acids are thought to be regulated inside the cell through

lipophagy 69. Palmitic acid (PA) and its effects on diabetes has been studied in rat
pancreatic beta cell line INS-1 77. It was determined to trigger autophagy independently
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of the mTOR pathway. For instance, autophagy was shown to be promoted by
stimulating JNK which leads to phosphorylation of Bcl-2 a resulting in its dissociation
from Beclin-1 which in turn allowed for the initiation of autophagy and autophagosome
formation 77. In addition, protein kinase C (PKC) isoforms δ, ɑ, and Θ have also been
implicated in PA-mediated autophagy regulation 78.
Studies suggest that in mice embryonic fibroblasts, PA, a saturated fatty acid can
induce autophagy 79. It was reported that palmitic acid was able to increase the amount of
LC3, suggesting an induction of autophagy. However, there was no increase in
phosphorylation of P70S6K or S6, two downstream proteins in the mTOR signaling
pathway 79. This suggests that PA induces autophagy independent of mTOR. PKCɑ was
identified and shown to be involved in the autophagy inducing process. When it was
knocked down with siRNA, LC3 detection fell 79. Furthermore, studies show that while
prolonged exposure to PA causes cell death, short term exposure induces autophagy, this
suggests that autophagy is an important protective measure against lipotoxicity caused by
PA 79.
PA has been shown to modulate autophagy via a secondary signaling pathway. Its
effects have been studied in the context of hepatic steatosis; a condition caused by high
amounts of fat in the liver 80. In hepatic steatosis, high lipid levels cause lipotoxicity.
Non-alcoholic steatohepatitis mice were fed a high fat diet. These mice were shown to
exhibit high autophagy mediated by PA 80. In these studies, autophagy was determined to
be regulated by the activation of mitogen activated protein kinase (MAPK), extracellular
signal-regulated kinase (ERK), P38, JNK. Based on these studies, researchers concluded
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that JNK-1 has a lipo-apoptotic effect while JNK-2 promotes autophagy and has a
cytoprotective effect (Figure 1.5) 80.
In addition to PA, myristic acid (MA) has been studied for its autophagy
regulating effects. Like palmitic acid, MA is a saturated fatty acid commonly used by the
body as a nutrient. In the context of autophagy, MA has been found to promote
overexpression of Beclin-1 gene BCN1 and increased conversion of LC3-I to LC3-II in
mouse cardiomyocytes 81. MA is thought to work to upregulate autophagy by producing
C14-ceramide and upregulating ceramide synthase 5 (Figure 1.5) 81.
Omega-3 polyunsaturated acids have been known to play a role in regulating
autophagy. The most studied of these is docosahexaenoic acid (DHA). DHA is a
component in many of the phospholipids that make up the cell membrane in the brain,
skin, and retinal tissue 82. It has been studied in myocardioblasts and various human
cancer cell lines 83-85. DHA has been implicated in the p53-AMPK-mTOR signaling
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Figure 1.5
Overview of regulation of autophagy by free fatty acids. Palmitic acid
stimulates autophagy by activating JNK and has been shown to interact with PKC
isoforms which have been implicated in autophagy regulation. Myristic acid has
been shown to upregulate autophagy by producing C-14 ceramide. DHA has been
implicated in the P53-AMPK-mTOR pathway resulting in activation of autophagy.
pathway. It has been shown to work through AMPK to inhibit mTOR and induce
autophagy in human cancer cells with wild type p53. 86. However, In prostate cancer cells
with mutant p53, DHA was observed to induce autophagy through the creation of
mitochondrial reactive oxygen species that results in the inactivation of AKT and mTOR
also resulting in an activation of autophagy (Figure 1.5) 87.
Finally, autophagy is related to cholesterol biosynthesis inversely through the
mTOR signaling pathway. When cholesterol biosynthesis is inhibited, there is an
induction of autophagy. Inhibition of cholesterol biosynthesis by statin drugs such as,
simvastatin has been linked to autophagy activation via the inhibition of the mTOR
signaling pathway in human blood cancer cells. It was determined that the statin drug
caused this activation only through cholesterol depletion when the cholesterol depleting
agent, methyl-β-cyclodextrin also produced an activation of autophagy 88. Likewise, a
deficiency of transmembrane 7 superfamily member 2 (TM7SF2), a positive regulator of
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cholesterol biosynthesis, results in repression of autophagy. Removal of TMS7F2 causes
increases in the expression of fatty acid degradative enzymes, decreased lipid
accumulation and in turn decreased autophagy in mice exposed to Lipopolysaccharide 89.
Conclusion and Future Perspectives
The aim of this review is to outline the current state in the field of lipid regulation
of autophagy. To that end, this review has discussed a myriad of ways in which many
lipids are involved in the process of autophagy and its regulation. All the lipids discussed
along with their functions and effects on autophagy have been summarized in Table 1.1
(Table 1.1). Autophagy represents a cellular process that has implications for several
important areas of study. Phospholipids and their derivatives have been shown to not only
be an important part of the regulation of autophagy through the crucial mTORC1
signaling pathway, but also an integral part of the autophagy machinery. These lipids
have also been shown to affect a variety of processes by acting through PPARs with
possible implication in human disease. Finally, dietary lipids and cholesterol have been
implicated in the regulation of autophagy both through the canonical mTOR pathway and
alternative means.
The role lipid molecules play in autophagy represents the potential for many new
avenues of research. Understanding it can give us a better, more holistic idea of this
process which is central to many cellular functions and disease states. As our
understanding of autophagy has grown, its activators and inhibitors have begun to appear
as a novel area of drug development. As a result, it is necessary to fill in the gaps in our
knowledge with regards lipid signaling. In the specific case of disease, it may be
necessary to identify novel lipid molecules involved in autophagy. It may also be helpful
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to determine if there is a link between the signaling pathways described or if they all act
independently. Finally, if autophagy is to be exploited as a potential treatment for disease,
it would be necessary to evaluate the effects these lipid molecules and signaling pathways
have on cellular functions related to autophagy.
Table 1.1

A Summary of Discussed Lipids Involved in Autophagy

Table 1.1. Summary of discussed lipids involved in autophagy
Lipid Name
Function
Effect on autophagy
is conjugated to LC3 and
required for autophagy
Phosphatidylethanolamine (PE)
incorporates into autophagosome
progression
elongation of autophagosome
posphatidylinositol-3-phosphate
required for autophagy
memebranes/ docking molecule
(PI3P)
progression
in selective cargo capture
phosphatidylinositol-4,-5inhibits PI3K-AKT-mTOR
activation of autophagy
bisphosphate (PIP2)
signaling pathway
phosphatidylinositol-3, 4, 5activates PI3K-AKT-mTOR
inhibition of autophagy
triphosphate (PIP3)
signaling pathway
induces membrane curvature in
required for autophagy
phosphatidic acid
autophagosomal vesicles/
progression/ activation
inhibits mTOR
autophagy
diacylglycerol (DAG)
activates Protein Kinase C
activation of autophagy
inhibits mTOR independently of
sphingosine-1-phosphate
activation of autophagy
AKT
inhibits AKT and, by extention,
ceramide
activation of autophagy
mTOR
abundance of triglycerides is
activation of autophagy/
triglycerides/lipid droplets
regulated by the cell through
inhibition of autophagy
autophagy of lipid droplets
activates Protein Kinase C/
palmitic acid (PA)
activation of autophagy
activates JNK
increases the production of
myristic acid (MA)
activation of autophagy
ceramide
inhibits AMPK-mTOR pathway
docosahexaenoic acid (DHA
through wild-type p53/ inhibits
activation of autophagy
AKT-mTOR through mutan p53
cholesterol
activates mTOR signaling
inhibition of autophagy

The technology we use to understand autophagy has increased greatly over the past years,
and it has allowed our understanding to grow. However, there is still progress to be made
especially with respect to the role lipids play in its regulation. For example, mass
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spectroscopy techniques have significantly improved in recent years allowing for the high
throughput analysis and identification of lipids present in a system. Other advances that
would facilitate new research could include an improved way of visualizing and even
purifying autophagosomes and lysosomes. Current methods utilize immunoprecipitation
or density gradient fractionation, both of which are known to result in significant levels
of impurities, to isolate these subcellular structures. In conclusion, lipids play an
important and diverse signaling role in autophagy regulation, and it is necessary to fully
characterize lipid signal transduction pathways to better inform autophagy-based
therapies.
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CHAPTER TWO: LIPIDOMIC ANALYSIS OF FABP5-BOUND AUTOPHAGY
REGULATORS IN DIFFERENTIATED SH-SY5Y CELLS
The motor features of Parkinson’s disease result from loss of dopaminergic
neurons in the substantia nigra with autophagy dysfunction being closely linked to this
disease. While a large body of work focusing on protein effectors of autophagy has been
reported, regulation of autophagy by lipids has garnered far less attention. We, therefore,
sought to identify endogenous lipid molecules that act as signaling mediators of
autophagy. In order to accomplish this goal, we assessed the role of fatty acid binding
protein (FABP) family members on autophagy. Knockdown of FABP5 resulted in
suppression of autophagy in retinoic acid-differentiated SH-SY5Y cells suggesting an
autophagic role for an interacting lipid. A lipidomic screen using FABP5, that is
expressed by dopaminergic neurons, as “bait” was devised and implemented to identify
lipid cargo. Our analysis has found significant hits that include 5-oxo-eicosatetraenoic
acid (5OE) and its precursor metabolite, arachidonic acid (AA). Long chain fatty acids
were also found to bind FABP5 that include stearic acid (SA), hydroxystearic acid (HSA)
and palmitic acid (PA). Addition of 5OE, SA and HSA but not AA or PA, led to potent
inhibition of autophagy in cultured dopaminergic cells. Correspondingly, heightened
mTOR signaling was also observed following 5OE, HSA and SA treatment. To identify
potential molecular mechanisms for autophagy inhibition by these lipids, RNA-Seq was
performed which revealed both shared and divergent signaling pathways. These findings
suggest a role for these lipids in modulating autophagy through diverse signaling
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pathways that may involve mTOR activity and could represent novel therapeutic targets
for Parkinson’s disease.
Introduction
Autophagy and Parkinson’s Disease
Parkinson’s disease (PD) is the second most frequent neurodegenerative disease
that is characterized by motor system dysfunction caused by loss of dopaminergic
neurons in the substantia nigra. Macroautophagy (subsequently denoted as autophagy)
plays an important role in PD as evidenced by disease-causing mutations in genes
directly involved in this essential cellular process 90. Autophagy is a fundamental process
for degrading macromolecules and organelles and is also the only cellular process known
to remove large protein aggregates 91. Therefore, defective autophagy is associated with
the pathophysiology of PD due to the presence of hallmark Lewy body inclusions 92. As
a result, autophagy has been of a keen focus for the development of PD therapy.
Autophagy is a highly ordered catabolic process which begins by targeting
material to be degraded through conjugation of p62 or by other mechanisms 93. Once
targeted, the material is engulfed by a lipid vesicle derived from the endoplasmic
reticulum. The lipid vesicle is created through the propagation of
phosphotidylethanolamine-Atg8 (LC3) lipoprotein complex. A vesicle with fully
enveloped cargo will fuse with multivesicular bodies and then lysosomes possessing
digestive enzymes to degrade the cargo into simple constituents that can be recycled for
metabolic purposes. This process occurs constitutively within cells however the rate and
targeted cargo can be modulated by numerous signaling pathways many of which
converge on a master regulatory complex known as TORC1 94.
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Regulation of Autophagy by Lipids
Advances in our understanding of autophagy have occurred largely through the
investigation of protein effectors of this process. However, little is known about the
contribution of endogenous lipid compounds to autophagy regulation. Principal
knowledge in this field has arisen from the study of AKT pathway activation by
phosphatidylinositol phosphorylation, largely in the context of growth factor signaling
and oncogenesis. Despite the reduced focus in this area, the involvement of
phosphatidylinositol indicates that lipids are indeed critical signaling mediators for
autophagy control. A limited understanding of other lipid contributors is likely due to the
inherent physical properties of these biomolecules, which include enhanced oxidation,
degradation and insolubility, rendering them difficult to study. Despite these limitations,
lipid research is becoming more accessible, largely as a result of advancements in mass
spectrometry resources (e.g., methods, databases) and the commercial availability of
lipids. As such, we have employed these tools to identify autophagy-relevant lipids.
FABP5 is an Intracellular Lipid Chaperone
There are 10 members of the FABP family (FABP1-9 and 12) present in humans.
As a group, these members transport fatty acids and other lipophilic compounds (e.g.,
eicosanoids and retinoids) within cells 95,96. Individually, these proteins have both
distinct and shared cargo lipids. The unique functionality of specific FABP members is
also suggested by diverse tissue and developmental expression, as well as an association
with human disease 96, 97. Therefore, this protein family represents a strong pool of
potential bait proteins for the identification of autophagy-regulating lipids. A detailed
examination of individual members has led to our specific interest in FABP5. Ewing et
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al., have provided evidence that FABP5 interacts with a known autophagy-regulating
protein (ATG5) as one of 368 bait proteins in a mass spectrometry-based interactome
screen 98. In addition, FABP5 expression has been reported to modulate PI3K/AKT
signaling99, which plays a central role in regulating autophagy via mTOR activity.
Furthermore, FABP5 might have particular relevance to PD since it has been reported
that its expression is highly enriched in nigral DA neurons 100. As a result, we began our
investigation into autophagy-regulating lipids by focusing on FABP5 interactors.
Dopaminergic SH-SY5Y cells
SH-SY5Y cells are human neuroblastoma cells derived from the SK-N-SH cell
line101; they are a widely used cellular model for PD due to their physiologic similarity to
dopaminergic neurons. These cells are commonly differentiated with all trans-retinoic
acid (RA) into a DA neuron-like postmitotic cell capable of generating action potentials
102, 103

. Systems genomic analysis using transcriptome sequencing coupled with

proteomic evaluation shows that SH-SY5Y cells have intact DA neuron signaling
pathways 104. RA-differentiated SH-SY5Y cells express mature DA neuron markers (TH,
VMAT2, DAT, PITX3, RET, DRD2) and produce high levels of dopamine 105. Evidence
also indicates that these cells, like mature DA neurons, have intact DRD2 signaling 105.
Consequently, differentiated SH-SY5Y cells are commonly used to model DA neurons
and were chosen for this study.
Materials And Methods
Cell Culture
SH-SY5Y human neuroblastoma cells, from ATCC, were cultured in T175 tissue
culture flasks and kept at 37°C with a 5% CO2 environment. Cells were cultured in
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DMEM/F12 50/50 mix (Corning Cellgro) with L-glutamine, 15% Fetal Bovine serum
(Atlanta Biologicals), 1% non-essential amino acids (Corning Cellgro), 1% PenicillinStreptomycin solution (HycloneTM, 1000 units/mL Penicillin- 10000μg/mL
Streptomycin) as previously described by Shipley, Mangold, & Szpara 106. Cells were
passaged when the flasks reached ~80%-90% confluency using 0.25% Trypsin, with
2.2mM EDTA and sodium bicarbonate (Corning). Cells at passage number 5-15 were
used for experiments. For experiments, cells were plated on multi-well tissue culture
plates at the necessary concentrations (e.g. 3 million cells per well on a 6-well plate).
Before experimentation, the cells were treated with 10 µM retinoic acid for 7 days, to
differentiate them into dopaminergic neuron-like cells. HEK 293T Human Embryonic
Kidney cells were grown in DMEM media with 1.0 g/L glucose with L-glutamine and
sodium pyruvate (VWR), 10% Fetal Bovine Serum (Atlanta Biologicals), and 1%
Penicillin-Streptomycin solution (HycloneTM, 1000 units/mL Penicillin- 10000μg/mL
Streptomycin) and passaged as described for SH-SY5Y cells.
Lipid Treatment of Cells
Stock solutions of 5-oxo-ETE (10mM), hydroxystearic acid (100mM),
arachidonic acid (100mM), palmitic acid (100mM), and stearic acid (100mM) were made
by dissolving each lipid in sterile 95% ethanol and stored at -80°C. Stock and dosage
concentrations were determined by using similar concentrations as those used in other
published studies within the literature 107-109. During experimentation, SH-SY5Y cells
were treated with each relevant lipid or the vehicle control (ethanol) dissolved into a
media solution consisting of DMEM/F12 50/50 mix (Corning Cellgro) with L-glutamine,
15% freshly thawed Fetal Bovine serum (Atlanta Biologicals), 1% Penicillin-
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Streptomycin solution (HycloneTM, 1000 units/mL Penicillin- 10000μg/mL
Streptomycin) for 4 hours followed by lysis.
Detergent-free Immunoprecipitation
FABP5-V5 tagged, overexpressing SH-SY5Y cells were plated onto a 100mm
cell culture dish and treated with retinoic acid for 7 days. Cells were then lysed using a
freeze-thaw lysis technique. During lysis, cells were washed twice with phosphate buffer
and frozen at -80°C for 15 minutes in 120 µL PBS. Cells were then thawed and scraped
into microcentrifuge tubes. Following lysis, the cells were centrifuged at 15000g for 10
minutes at 4°C and the supernatant was collected. The supernatant was incubated with
either V5 antibody (D3H8Q, Cell Signaling Technology, catalog no. 13202S) or IgG
isotype control antibody (Cell Signaling Technology, catalog no. 3900) for 1 hour at 4°C
on rotation. Following primary antibody incubation, ChIP grade protein G magnetic
beads (Cell Signaling Technology, catalog no. 9006S) were added and the supernatant
was rotated at 4°C. Then the magnetic bead complexes were pelleted and washed twice
with PBS and once with ddH2O. Water was then removed, and magnetic bead pellets
were resuspended in a 2:1 chloroform: methanol solution and sent for lipidomic analysis
at The Emory University Lipidomics Core Facility.
Western Blotting
Western blots were run using the Life Technologies products. Before western
blotting, cells were washed with PBS, lysed with RIPA lysis buffer containing a protease
inhibitor cocktail and subsequently sonicated at 80% intensity for 7 seconds. Following
sonication, cells were sonicated at 15000g for 10 minutes at 4°C, and the supernatant was
then collected. Polyacrylamide Gel Electrophoresis was then performed on the protein
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extracts on either a 4-12% or 16% pre-cast gel, depending on the size of the protein
assayed and the band separation required for proper analysis. Electrophoresed proteins
were transferred onto a PVDF membrane using the iBlot2 Dry transfer device and
transfer materials. The transfer was performed according to the manufacturer’s
instructions with the iBlot2 device.
Primary antibodies were used to detect LC3 (Novus Biologicals, catalog no.
NB100-2220), FABP5 (Cell Signaling Technology, catalog no. 39926S), Phospho- S6
Ribosomal protein (Ser 235/236) (Cell Signaling Technology, catalog no.4858S), and βactin (Thermo Fisher, catalog no. MA1-91399). Anti-rabbit (Cell Signaling Technology,
catalog no. 7074) and anti-mouse (Cell Signaling Technology, catalog no. 7076) HRP
secondary antibodies were used to probe western blot PVDF membranes after primary
antibody incubation. Pierce ECL Western Blotting substrate (Thermo Scientific) was then
used to develop membranes. Membranes were imaged on a Bio-Rad blot imager. Protein
expression was analyzed by taking densitometry measurements on the images obtained,
using ImageJ and Microsoft Excel.
Lentiviral Production and Transduction
A Thermo Fisher Virapower kit was used to produce lentivirus. HEK 293T
Human embryonic Kidney cells (ATCC) were transfected with the transgene-carrying
plasmids, together with plasmids containing lentiviral packaging components, using
lipofectamine 2000 (Life Technologies). Lentiviral packaging plasmids LP1 and LP2 as
well as coat protein plasmid VSV and the desired transgene plasmid vector (7.2 µg of
each) were incubated with Lipofectamine 2000 in Opti-MEM media (Gibco) for 20
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minutes at room temperature. The mixture was then added dropwise to flasks containing
293T cells in fresh media. The next day, media was replaced with fresh media. The
following day, the supernatant containing full assembled, active lentivirus was collected
and filtered through 400nm pore filters. Filtered supernatant media was aliquoted as
needed and stored at -80°C until ready for use. For transduction into target cells,
aliquoted virus-containing media was added directly to the media bathing the target cells
in their flasks. The following day, media was replaced with fresh media. Puromycinbased selection for shRNA constructs was initiated three days after viral addition and
maintained for the duration of the experiment.
LC3B-GFP-Mcherry Puncta Assessment
SH-SY5Y cells were plated into 24-well plates containing poly D-lysine coated
coverslips. Cells were transduced with lentiviral stocks containing the FUW McherryGFP-LC3 plasmid obtained as a gift from Anne Brunet (Addgene, plasmid # 110060) 110.
The following day virus-containing media was replaced with fresh media. 48 hours after
initial transduction cells were differentiated into neurons with 10 µM RA for 7 days.
Following the differentiation period, cells were treated with relevant lipids for 4 hours.
Treated cells were then fixed with 4% paraformaldehyde (in PBS) for 23 minutes on ice.
The glass coverslips with attached cells were then washed with PBS and incubated in
1:10000 Hoechst dye in PBS for 5 minutes on ice and in the dark and washed again.
Finally, the coverslips were mounted on glass slides for fluorescent imaging using
Fluoromount G. Glass slides were imaged on the EVOS M5000 imaging system (Thermo
Fisher Scientific) at 60x objective magnification with the automated z-stack function.
Red only puncta and green only puncta were counted with ImageJ on each image
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produced and a value for flux was determined as the ratio of red only puncta to total
puncta for each image. This processing was automated via macro to create objective
quantification of puncta.
RNA Extraction
SH-SY5Y cells were plated onto 6-well plates and treated with either vehicle
control (ethanol), 5OE (40 µM), SA (400 µM) or HSA (400 µM) for 6 hours. Following
treatment, cells were lysed using the materials included in the Qiagen RNeasy RNA
extraction Minikit (catalog no, 74104). Total RNA was extracted with included materials
according to the manufacturer’s protocol. RNA concentrations and purity were measured
using a spectrophotometer (Implen Pearl nanophotometer).
RNA Seq
Extracted RNA was sequenced and analyzed by Novogene. Briefly, RNA was
poly-A captured (rRNA depleted), RNA fragmented and cDNA synthesized. Sequencing
was performed using an Illumina NovaSeq 6000 system. Analysis was performed for
paired-end 150 bp reads with ≥ 20 million reads per sample. A differential gene
expression analysis was performed and KEGG and Reactome annotated pathways
enrichment determined.
Results
FABP5 is Expressed by Dopaminergic Neurons in the Substantia Nigra
In situ hybridization data, provided by the Allen Brain Institute, transcriptomics
previously reported100 and our immunohistochemical analysis (Figure 2.1) indicates that
FABP5 mRNA and protein expression is enriched in dopaminergic neurons within the
substantial nigra of mouse brain, a region that possesses dopaminergic neurons whose
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loss results in the hallmark motor features of PD. As a result, we chose to utilize a human
neuroblatoma cell line (SH-SY5Y) for this investigation that can be differentiated into
post-mitotic dopaminergic neuron-like cells. These cells are widely employed by PD
researchers and, due to their ready production of post-mitotic neuron-like cells, they are
also used broadly across neuroscience disciplines including AD, ALS and HD research
111

.

Figure 2.1. FABP5 is expressed by nigral dopaminergic neurons. In situ
hybridization for Tyrosine hydroxylase (A) and Fabp5 (B) mRNA expression [Mouse
Brain Atlas, Allen Brain Institute]. Immunohistochemistry was performed for
FABP5 (C) and Tyrosine Hydroxylase (D) in adult mouse brain substantia nigra
with nuclei labeled using DAPI and merged image shown (E). Scale bar = 400 µm.
FABP5 Regulates Autophagy
To address whether FABP5 affects autophagy, we engineered SH-SY5Y cells to
stably express scrambled or FABP5 shRNA. A pure population of transgenic cells was
then obtained by selection with puromycin. SH-SY5Y cells were then differentiated into
post-mitotic dopaminergic neuron-like cells with 7 days of 10 µM of all-trans retinoic
acid (RA) supplemented to growth media as previously described 111, 112. Autophagic flux
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was determined by comparing the autophagosome marker LC3B-II in untreated versus
bafilomycin A1 treated cultures (Figure 2.2A, B) 113. We also monitored autophagic flux
by quantifying autophagosome/lysosome ratios observed in mCherry-GFP-LC3B
transgene-expressing cells (Figure 2.2C, D) as previously described 113, 114. Our data
indicates that FABP5 knockdown results in impaired autophagy. In addition, we found
that neither FABP5 knockdown nor overexpression affected SH-SY5Y differentiation
(Figure 2.3), indicating that differences in these cells were not due to altered RA
signaling or differentiation status.

Figure 2.2. FABP5 regulates autophagy. (A) Undifferentiated or RAdifferentiated SH-SY5Y cells were transduced with lentivirus containing scrambled
(Cntrl) or FABP5 shRNA constructs and LC3B-IIexpression evaluated by western
blot and (B) autophagic flux determined. (C) Representative images for mCherrygfp-LC3B that was transduced by lentivirus into RA-differentiated control or
FABP5 knockdown as described in A. and then autophagosome (yellow) and
lysosomes (red) quantified (D). *p<0.05, error bars = SEM.
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Figure 2.3. FABP5 does not affect SH-SY5Y differentiation by RA. SH-SY5Y
cells were transduced with lentivirus containing a scrambled (control) shRNA,
FABP5 shRNA or an FABP5 overexpression (OVER) construct. Cells were selected
for transgene expression using puromycin and treated with all-trans RA (10 µM) for
the indicated times and Tyrosine Hydroxylase (TH) and Dopamine receptor D2
(DRD2) protein levels were assessed by western blot. 3 biological replicates are
shown.
5OE, AA, HSA, SA and PA Interact with FABP5
Having established an autophagy regulating function for FABP5, we next employed
FABP5 as a bait protein to identify lipid interactors. We created an SH-SY5Y cell line
using a lentivirus that stably expressed FABP5 with a V5 epitope tag. A detergent-free
immunoprecipitation protocol was developed to co-purify FABP5 and associated lipids
(Figure 2.4A). Cells were RA-differentiated for 7 days and then treated with media
containing fresh FBS for 1 hour. FABP5-lipid complexes were then purified and sent to
the Emory University lipidomics core for analysis. Six lipids (one unidentifiable by mass)
were found to exhibit FABP5 binding (Figure 2.4B). Arachidonic acid (AA) was identified
in this group and is well-studied as a precursor for a diverse set of metabolites, including
5-Oxo-eicosatetraenoic acid (5OE), another FABP5 interactor found in this analysis. Long

35
chain fatty acids were also identified that include hydroxystearic acid (HSA), stearic acid
(SA) and palmitic acid (PA).

Figure 2.4. FABP5 lipidomic interactome.(A) FABP5 was successfully
immunoprecipitated (IP) with a detergent-free method using lysate obtained from
RA-differentiated SH-SY5Y cells that stably express a recombinant FABP5-V5.
Immunoprecipitations (V5 epitope tag-specific or antibody isotype control) were
performed for 1 hr or overnight (O/N) and western blotting done using an FABP5
antibody. (B) Samples obtained by 1 hr FABP5-V5 IP (V5) or control antibody IP
(Control) from 3 independent biological replicates were processed for lipid
extraction and analyzed by QTRAP 5500 mass spectrometer via Exion LC AC
autosampler. Six lipids were identified to have significant interaction with FABP5.
Autophagy Inhibition by 5OE, HSA and SA but not AA or PA
We next examined whether each of these five candidates affected autophagy in
differentiated SH-SY5Y cells. We found that 5OE, HSA and SA, but not AA or PA,
exhibited potent dose-dependent anti-autophagic activity at concentrations reported in
human serum115–117 as well as in other systems (Figures 2.5, 2.6) 118–120. Interestingly, AA
shows an altered lysosome/autophagosome ratio following quantification of mCherryGFP-LC3B puncta (Figure 2.6) indicative of autophagy inhibition.

However, an

examination of LC3-II levels following bafilomycin treatment (Figure 2.5C., D) has
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Figure 2.5. Effect of candidate lipids on LC3B-II autophagic flux. (A,C,E,G,I)
Increasing amounts of lipid or vehicle (ethanol) were added to RA-differentiated
SH-SY5Y cells for 4h in the presence or absence of bafilomycin A1 (Baf A1) and
western blotting performed and autophagic flux was determined (B,D,F,H,J) from 3
biological replicates. *p< 0.05, error bars = SEM.
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revealed no effect on autophagic flux. We observed that at 4 hours of treatment large
numbers of cells were detached in the two higher doses of AA, suggesting toxicity. This
was confirmed at 24 hours of treatment (data not shown). Given many shared mechanisms
between autophagy and apoptosis, these results suggest AA induces death rather than
autophagy 121.

Figure 2.6. Effect of candidate lipids on LC3B puncta autophagic flux. Lentivirus
was used to transduce RA-differentiated SH-SY5Y cells with mCherry-gfp-LC3B.
Seven days later, cells were treated with ethanol (vehicle) or lipid at the highest two
does for 4h. Representative images (A) are shown for the highest lipid dose and
autophagosomes (yellow) and lysosomes (red) were then quantified (B). *p < 0.05,
error bars = SEM.
Treatment with 5OE, HSA or SA Enhances mTORC1 Pathway Signaling
The mammalian target of rapamycin complex 1 (mTORC1) complex is a master
regulator of autophagy via integration of numerous and diverse signaling pathways 122.
To further validate autophagic flux data for 5OE, HSA and SA, we assessed their
activation of mTORC1. We tested whether candidate lipids could regulate mTORC1
activation by treating differentiated SH-SY5Y cells with autophagy inhibiting doses of
5OE, HSA or SA and measured the activation of a canonical mTORC1 substrate, S6, by
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western blot (Figure 2.7). An increase in the phosphorylation of S6 at mTORC1associated residues (S240/S244) was observed following 5OE and HSA at 15 min (Figure
2.7C) and SA at 1 hr (Figure 2.7D) compared to vehicle. Activation of S6 was largely
unchanged at 1h and 2h post-treatment with the exception of SA. No effect was observed
by PA treatment. It should be noted that lipids were gently but thoroughly mixed with
fresh media containing 15% FBS by tube inversion and added to cells at time zero. FBS
possesses lipid carrier proteins (e.g., albumin) to facilitate proper shuttling of lipids to
cultured cells in a physiological manner. Also note, that the initial robust increase in pS6
(at 30 min) in vehicle-treated cells is likely due to enhanced mTOR signaling resulting
from this addition of fresh FBS-containing media. However, 5OE, HSA and SA alter this
dynamic. This data supports an autophagy-inhibiting role for 5OE, HSA and SA and
suggests that this could involve an mTORC1-mediated mechanism.
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Figure 2.7. mTOR pathway activation by 5OE, HSA, SA, and PA. SH-SY5Y cells
were differentiated with RA and then subjected to ethanol (vehicle), 5OE, HSA, SA
or PA for the indicated concentrations and times in freshly prepared culture media.
Western blotting (A, B) was then performed for pS6 (Ser240/244) following
treatment at the indicated times. Densitometry was assessed for pS6/B-Actin for
each condition and time point normalized to vehicle for each time point (C, D). *p <
0.05, error bars = SEM versus vehicle group at each time point.
5OE, HSA and SA Do Not Induce Cell Death
Autophagic mechanisms can share features with apoptosis 123. Therefore, we
examined whether the lipids, 5OE, HSA or SA, which exhibited an autophagy-regulating
profile in both autophagic flux assay (Figures 2.5 and 2.6) induced death in differentiated
SH-SY5Y cells. These lipids did not exhibit toxicity after 24 hours of treatment (Figure
2.8) indicating that apoptosis is not confounding autophagic flux data. Interestingly,
despite structural similarity, AA showed robust toxicity at 100uM and 400uM doses (data
not shown) suggesting divergent effects with 5OE.
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Figure 2.8. 5OE, HSA, SA and PA do not induce cell death. RA-differentiated
SH-SY5Y cells were treated with ethanol (vehicle), 5OE, HSA, SA or PA as shown
in normal growth media. After 24h, cell death was measured by (A, C) LDH
released into the culture media as well as y the (B, D) resazurin assay. *p < 0.05,
error bars = SEM.
Transcriptomic Alteration of the PPAR Pathway by HSA
We next sought to gain insight into the molecular mechanism of action for
autophagy-inhibiting lipid candidates. RNA Seq (random primed with 44M-60M
reads/sample) was performed on RA-differentiated SH-SY5Y cells treated with vehicle
(ethanol) or lipid (5OE: 4 µM, HSA: 400 µM, SA: 400 µM) for 6 hours. Unbiased
analysis for transcript enrichment for KEGG and Reactome annotated pathways was
performed (Figure 2.9). Large numbers of differential transcripts for both HSA and SAtreated cells were identified (Figure 2.9H, I). However, only a very modest number of
differential transcripts in the 5OE group was found (Figure 2.9G) which reduces the

41
pathway associations as evidenced by only one significant hit (amyotrophic lateral
sclerosis). For this reason, we also listed the top associated pathways that were not
significant. Interestingly, the mTOR signaling pathway was such a hit. Both HSA and
SA exhibited associations with cell cycle regulation, fatty acid metabolism and
peroxisome proliferator-activated receptor (PPARA) signaling.
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Figure 2.9. RNA Seq analysis of lipid treatment.KEGG annotated pathways for
RA-differentiated SH-SY5Y cells treated with (A) 4 µM 5OE, (C) 400 µM HSA and
(E) 400 µM SA for 6h. (B, D, F) Reactome pathways are also shown for each
treatment. *significance versus vehicle treatment group; 3 biological replicates.
Volcano plots for (G) 4 µM 5OE, (F) 400 µM HSA and (G) 400 µM SA are shown
(red dots = up regulated genes, green dots = down regulated genes).
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Discussion
Despite intense efforts to harness autophagy for therapeutic benefit, very few
clinical applications have been realized 124. Consequently, the strong association between
autophagic dysfunction and neurodegenerative diseases like PD has spurred investigation
into more diverse targets for autophagy regulation. This rationale prompted us to devise
a lipidomic screen for identification of autophagy-controlling lipids. Our study has
identified three lipids, 5OE, HSA and SA, with potent anti-autophagic activity when
applied to cultured dopaminergic cells at physiological concentrations found in human
serum. In addition, this work has uncovered FABP5 as a regulator of autophagy, likely
through the activity of lipid cargo.
5OE and AA are both well-established signaling lipids that were significant hits in
our FABP5 interactome screen. AA also serves as the precursor for a diverse set of
bioactive lipid signaling molecules making it of great interest in human physiology and
disease 125. Nevertheless, since we do not observe a direct effect on autophagy in our
system, we did not explore AA biology further. We do note, however, that AA is an
interactor of FABP5 and a precursor for 5OE, which provides additional evidence for a
physiological FABP5-5OE interaction. 5OE can be produced and released locally or as a
precursor metabolite (5-HETE) released and metabolized by the target cell into 5OE (via
transcellular biosynthesis) 126. 5OE has been well-studied for its role as an inflammatory
cytokine that can affect a wide range of leukocytes 127. However, 5OE is reported to
exhibit the greatest potency on eosinophils as both a chemotactic agent and a stimulant,
suggesting an anti-parasitic or allergic response role 127,128. Interestingly, previous work
has uncovered another allergy response pathway expressed by dopaminergic neurons that
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sensitizes these cells to death 129. This raises the question of whether dopaminergic
neurons are susceptible to cell stress induced by allergic response signaling. A possible
explanation for heightened expression of FABP5 in dopaminergic neurons of the
substantia nigra (Figure 2.1) is to sequester 5OE due to enhanced sensitivity toward this
mode of allergic response signaling.
Our data supports a direct role for 5OE upon dopaminergic neurons, which is
consistent with reports of other proinflammatory cytokines (e.g., IL-6, TNF-alpha) 130.
While there are reports of an oxoeicosanoid receptor 1 (OXER1)131 that can interact with
5OE as well as other eicosanoids, leukotrienes and 5OE metabolites132, it is likely not
responsible for autophagy inhibition by 5OE that we observe. This is because OXER1 is
a plasma membrane-bound G-protein-coupled receptor, while our isolated FABP5-5OE
complexes reside within the cytoplasm (mild, detergent-free immunoprecipitation). We
have also observed that FABP5 suppression by shRNA inhibits autophagy, indicating a
cytoplasmic role for 5OE.
HSA and SA are long-chain fatty acids with an 18-carbon backbone that were also
identified by our FABP5 lipidomic interactome screen. SA is a lipid commonly found at
high levels in a large number of food products, including grains, milk, meat, and dairy.
Thus, all individuals have some exposure to this compound. There are no reports of
direct toxicity from SA. However, mounting evidence implicates this dietary lipid as a
potential regulator of cell cycle and tumorigenesis, albeit with conflicting reports 108, 133.
Metabolic derangement has also been noted in cells and rodents following SA exposure
134

. Further study of SA is likely warranted given the ubiquitous presence of this lipid in

food products and the newly found association with autophagy inhibition reported here.
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The addition of a single hydroxyl group to SA at the 12th carbon results in the
creation of HSA. While HSA is not a natural food compound, it is found in considerable
amounts in a large number of consumer products and can be produced by microbiota
from oleic acid and could provide a natural source of unknown dosage in animals 135.
The synthetic addition of the hydroxyl group to SA provides favorable handling
characteristics (waxiness), leading to the wide adoption of HSA in cosmetic products
(e.g., shampoo, underarm deodorants, lipsticks and more). Similar to SA, the study of
HSA has suggested its potential involvement in regulating tumorigenesis 136, 137. In line
with this observation, we found a strong association with cell cycle alteration and
oncogenic pathways in our RNA Seq analysis of HSA-treated cells (Figure 2.9).
Interestingly, both SA and HSA exhibited strong associations with PPAR signaling
pathways for KEGG and Reactome annotated pathways in our analysis. PPAR alpha and
delta are known to propagate lipid signaling through FABP5 interaction 138, 139 suggesting
that this is a pathway of interest for further study of autophagy inhibition.
In summary, we report that FABP5 regulates autophagy in dopaminergic cells.
Our subsequent lipidomic interactome screen identified five FABP5 interactors. Of these
interactors, 5OE, HSA and SA were confirmed to inhibit autophagy in dopaminergic
neurons. RNA Seq analysis for 5OE yielded few clues to mechanism of action due to
low differential transcript expression versus control. Conversely, transcriptomic
assessment for both HSA and SA indicates a strong association with altered PPAR
signaling which provides an intriguing target for further investigation into HSA/SAFABP5-mediated autophagy inhibition. Overall, these results indicate that identification
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of lipids that modulate autophagy could be a fruitful avenue for developing novel
therapeutics.
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Central Nervous System and Peripheral Cell Labeling by Vascular Endothelial
Cadherin-Driven Lineage Tracing in Adult Mice
Citation: Soto-Avellaneda, A., & Morrison, B. (2020). Central nervous system and
peripheral cell labeling by vascular endothelial cadherin-driven lineage tracing in adult
mice. Neural Regeneration Research, 15(10), 1856–1866. https://doi.org/10.4103/16735374.280317
Abstract
Understanding the contribution of endothelial cells to the progenitor pools of adult
tissues has the potential to inform therapies for human disease. To address whether
endothelial cells transdifferentiate into non-vascular cell types, we performed cell lineage
tracing analysis using transgenic mice engineered to express a fluorescent marker
following activation by tamoxifen in vascular endothelial cadherin promoter-expressing
cells (VEcad-CreERT2; B6 Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze). Activation of target-cell
labeling following 1.5 months of ad libitum feeding with tamoxifen-laden chow in 4–5
month-old mice resulted in the tracing of central nervous system and peripheral cells that
include: cerebellar granule neurons, ependymal cells, skeletal myocytes, pancreatic beta
cells, pancreatic acinar cells, tubular cells in the renal cortex, duodenal crypt cells, ileal
crypt cells, and hair follicle stem cells. As Nestin expression has been reported in a subset
of endothelial cells, Nes-CreERT2 mice were also utilized in these conditions. The tracing
of cells in adult Nes-CreERT2 mice revealed the labeling of canonical progeny cell types
such as hippocampal and olfactory granule neurons as well as ependymal cells.
Interestingly, Nestin tracing also labeled skeletal myocytes, ileal crypt cells, and sparsely
marked cerebellar granule neurons. Our findings provide support for endothelial cells as
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active contributors to adult tissue progenitor pools. This information could be of particular
significance for the intravenous delivery of therapeutics to downstream endothelialderived cellular targets. The animal experiments were approved by the Boise State
University Institute Animal Care and Use Committee (approval No. 006-AC15-018) on
October 31, 2018.
Introduction
Identifying cell populations in adult mammals that undergo regeneration and
determining the source of progenitors can inform therapeutic strategies for a wide range of
human diseases. For such strategies to succeed, consideration must be given to the
contributions of non-canonical mechanisms for tissue regeneration. Supporting this notion is
accumulating evidence indicating the existence of naturally occurring transdifferentiation
mechanisms for adult cell replenishment (Michalopoulos et al., 2005; Tang et al., 2012;
Tarlow et al., 2014; Merrell and Stanger, 2016). Endothelial cells are key players in human
disease (Donato et al., 2015) while also representing an understudied potential pool of adult
progenitor cells. These cells are particularly promising candidates due to the possibility of
using intravenous genetic manipulation to target difficult to reach cell populations, such as
those of the central nervous system, in conjunction with vectors currently employed in
clinical trials (e.g., adeno-associated virus). Endothelial transdifferentiation would also offer
an explanation for reported extravascular effects following intravenous delivery of viral
vectors in humans and laboratory model systems. The proximity to all tissue types and a
well-described association with adult progenitor cells (e.g., the perivascular stem cell niche)
(Oh and Nör, 2015; Tamplin et al., 2015) provide additional rationale for further examination
of endothelial cells in this context.
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A growing body of evidence supports adult endothelial cell plasticity. For example,
primary mouse neural progenitor cells have been observed to spontaneously differentiate into
endothelial cells in culture (Wurmser et al., 2004). In addition, there is evidence that
populations of adult neuronal progenitor cells migrate from the meninges, a region
possessing a high concentration of endothelial cells (Bifari et al., 2017). Another area of
attracting increased interest is the study of the endothelial-mesenchymal transition, which is a
natural transdifferentiation phenomenon undertaken by endothelial cells and is an element of
normal cardiac development (Bernanke and Markwald, 1982; Mjaatvedt et al., 1987;
Eisenberg and Markwald, 1995; Camenisch et al., 2002; de Lange et al., 2004) that may also
underlie several forms of vascular disease (Chen et al., 2015; Moonen et al., 2015; Li et al.,
2018). Lastly, there is evidence that in adult rodents, specialized endothelial cells can dedifferentiate to become smooth muscle cells and chondrogenic cells following vascular injury
(Tang et al., 2012). These multipotent endothelial cells have been reported to readily
differentiate into diverse cell types, including neurons in vitro (Tang et al., 2012). Taken
together, these findings blur the line between endothelial cells and other cell types,
suggesting that endothelial cells could be attractive targets for cell lineage tracing analysis in
an adult mammalian system.
The development of innovative cell lineage tracing approaches has accelerated
research efforts in the field of regenerative medicine. Traditional cell lineage tracing
methods that rely upon the labeling of replicated DNA (e.g., BrdU, [3H]-thymidine)
would be expected to underreport transdifferentiation events due to the absence of cell
division in this process. To address the limitations of traditional approaches, cell lineage
tracing strategies that utilize a permanent fluorescent reporter activated by temporally-
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controlled genetic alteration have become prevalent (Kretzschmar and Watt, 2012).
Therefore, to carry out a comprehensive cell lineage tracing study of endothelial
transdifferentiation, we employed such a strategy that utilized an adult transgenic mouse
model for specific temporal labeling of endothelial cells. Mice were sacrificed at varied
intervals following the labeling period and 23 tissue types were assessed for the presence
(or absence) of a fluorescent marker to identify cellular progeny.
Materials and Methods
Animals
All mouse procedures and husbandry were approved by the Boise State University
Institute Animal Care and Use Committee (approval No. 006-AC15-018) on October 31,
2018. Mice were maintained in the Boise State University rodent vivarium at 25°C with 12hour light/dark cycles and provided food ad libitum. VEcad-CreERT2 transgenic mice were
kindly gifted by University of California, Los Angeles, USA (Monvoisin et al., 2006). NesCreERT2 transgenic mice (stock# 016261) (Battiste et al., 2007) and B6 CgGt(ROSA)26Sortm9(CAG-tdTomato)Hze reporter mice (stock# 007909) (Madisen et al., 2010) were
purchased from Jackson laboratory (Bar Harbor, ME, USA). Cell lineage tracing experiments
were initiated by replacing standard rodent pellets with chow containing 400 mg tamoxifen
citrate/kg chow (Cat# TD.130860; Envigo, Huntingdon, Cambridgeshire, UK) as described
previously (Albright et al., 2016; Rahman et al., 2017). After 1.5 months of tamoxifen
treatment, the chow was replaced with standard rodent pellets. Both female and male 4–5month-old mice were used in this study and no sex-linked variation in lineage tracing was
observed. Genotyping for transgenic mouse lines was performed as described previously
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(Monvoisin et al., 2006; Battiste et al., 2007; Madisen et al., 2010). At least two mice per
cohort were examined for reporter expression.
Tissue Preparation and Cryosectioning
Study mice were anesthetized with isoflurane followed by transcardial perfusion with
heparin (20 U/mL) in neutral phosphate buffer (PB) and then 4% paraformaldehyde (PFA) in
PB. Tissue was harvested and placed in ice-cold 4%PFA/PB and stored for 24 hours at 4°C.
Samples were then transferred to a 30% sucrose/PB solution for storage at 4°C for 72 hours.
Tissue was then dried and frozen rapidly in optimal cutting temperature (OCT) media on a
block of dry ice. Samples were then wrapped in aluminum foil, placed in freezer bags and
stored at –80°C until sectioning. Tissues were equilibrated to –20°C and then sectioned using
a cryostat (model CM1950; Leica, Buffalo Grove, IL, USA) at a thickness of 15 µm directly
onto Superfrost Plus Gold microscope slides (Thermo Fisher, Waltham, MA, USA). Slides
were dried in a dark drawer overnight. The next day, slides were processed for labeling or
placed in a slide holder, sealed, and stored at –80°C.
Hoechst Dye Labeling
Slides were removed from –80°C storage and allowed to equilibrate to room
temperature in a dark drawer. Slides were then washed with PB and labeled with a 1:20,000
dilution of Hoechst 33342 dye (Cat# H3570; Thermo Fisher) for 10 minutes at room
temperature. One PB wash was performed and sections were then allowed to dry in a dark
drawer for 30 minutes. Coverslips were then mounted using Everbrite mounting media (Cat#
23003; Biotium, Fremont, CA, USA). Slides were allowed to dry in a dark drawer for 24
hours and then stored in a slide box at 4°C until viewed.
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Immunohistochemistry
Section-containing slides were removed from –80°C storage and dried for 1 hour in
the dark at room temperature. Antigen retrieval was performed as previously described
(Hussaini et al., 2013). Slides were washed with PB and then placed in a container with
citrate solution (Cat# 14746S; Cell Signaling, Danvers, MA, USA) diluted in dH2O that was
preheated in a microwave (5 minutes at high power). The solution with slides was then
heated in a microwave for an additional 7 minutes at high power. The heated container was
then covered and placed in an ice bath for 1 hour. Slides were then washed three times with a
Tris solution (50 mM Tris HCl, 150 mM NaCl, 0.05% Triton X100-not pH adjusted). A pHadjusted Tris solution was used (TBST: 50 mM Tris HCl, 150 mM NaCl, 0.05% Triton
X100- pH 7.2) as a final wash. The slides were then dried for 30 minutes and primary
antibodies were then diluted in TBST supplemented with donkey serum to 4%. The primary
antibodies used in this study are as follows: anti-mCherry (Cat# MBS448092; 1:100;
Mybiosource, San Diego, CA, USA), anti-NeuN (Cat# 24307S; 1:100; Cell Signaling), antiinsulin (Cat# 3014S; 1:800; Cell Signaling), anti-glucagon (Cat# sc-514592, 1:100; Santa
Cruz Biotechnology, Dallas, TX, USA), and anti-K15 (Cat# sc-47697; 1:100; Santa Cruz
Biotechnology). Antibody solutions were incubated in a humidifying slide chamber at room
temperature overnight. The next day, slides were washed with TBST and incubated with the
appropriate secondary antibodies diluted in TBST with donkey serum to 4% for 2 hours at
room temperature. The secondary antibodies used in this study are as follows: donkey antigoat Alexa 594 (Cat# A32758; 1:500; Thermo Fisher), donkey anti-mouse Alexa 488 (Cat#
A-21202; 1:500; Thermo Fisher) and donkey anti-rabbit Alexa 488 (Cat# A-21206; 1:500;
Thermo Fisher). Slides were washed with TBST and then incubated with a 1:20,000 dilution
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of Hoechst 33342 dye (Cat# H3570; Thermo Fisher) at room temperature for 10 minutes. A
final wash in PB was performed and slides were then dried for 1h in a dark drawer. Once dry,
the slides were mounted with coverslips using Everbrite mounting media (Cat# 23003;
Biotium). The coverslips were allowed to dry for 24 hours in a dark drawer before imaging
or storage at 4°C.
Imaging and assessment of tissue sections
Conventional fluorescence microscopy images were obtained using an EVOS
M7000 Imaging System (Thermo Fisher). Hoechst images were viewed using a DAPI
filter cube and tdTomato was assessed using an RFP filter cube in the EVOS system.
Semi-quantitative assessment of tdTomato+ve cells was performed by comparing three or
more comparable levels of a tissue section obtained from at least two mice per cohort.
Cells were counted at 100× fields and a relative number of “+” signs assigned. When
comparing across different cohorts within a tissue group, the number of + signs correlate
to relative increases or decreases in tdTomato +ve cell number. As such, this method is
not stereological but provides a strong correlation with the relative abundance of cells
expressing tdTomato. Confocal microscopy images were acquired using the following
systems: Zeiss Laser Scanning Confocal Microscope Meta 510 system (Zeiss, White
Plains, NY, USA), Zeiss 880 Airy Scan system and an Olympus FV3000 Laser Scanning
Confocal Microscope system (Olympus, Center Valley, PA, USA). A supplemental image
database containing representative conventional fluorescence microscopy images (EVOS
M7000 system) from all examined tissues can be found at the Open Science Framework
(https://osf.io/x9yu8).
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Results
VE-cadherin cell lineage tracing labels a diversity of cell types in adult mice
Endothelial cell labeling was performed using a double transgenic mouse system that
allows for VE-cadherin promoter-specific expression of a CRE-recombinase (VEcadCreERT2) (Monvoisin et al., 2006), kindly provided by Dr. Iruela‐Arispe (UCLA)) that is
activated at designated times by the addition of tamoxifen (TAM) to rodent chow (Figure
A1). Following activation by TAM, CreERT2 excises a loxP-flanked DNA cassette
containing a stop codon within a transgenic CAG-promoter-driven tdTomato reporter
(Gt(ROSA)26Sortm9(CAG-tdTomato)Hze) (Madisen et al., 2010), resulting in permanent
and constitutive expression of tdTomato. VE-cadherin-directed CreERT2 expression was
selected due to the high degree of endothelial cell specificity reported in adult mice (Heimark
et al., 1990; Monvoisin et al., 2006). We also observed prototypical endothelial cell tracing in
these mice (Additional Figure 1). For this study, we sought to extend the labeling period to
1.5 months to enhance the tagging of transient endothelial cell populations not covered by
previous studies (Figure A1B). In addition, we lengthened the post-labeling phase (1.5, 3,
and 6 months) for increased capture of slow transdifferentiation events. A summary of the
results for the examined cell types and tissues is found in (Table A1). In addition, a
repository of images containing transgenic mouse lines, tissues, and experimental time points
has been provided in Additional file 1.
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Figure A1
Transgenic mouse cell lineage tracing strategy. (A). Adult mice (4–5
months of age) possessing a transgenic cassette containing either vascular endothelial
cadherin (VEcad)- or Nestin-promoter-driven.CreERT2 recombinase are fed tamoxifen
(TAM) citrate-laden chow to acti- vate loxP site-directed excision of a second transgene
(Ai9 line) possessing a translation stop codon sequence. Removal of this stop codon
results in CAG promoter-driven reporter expression of tdTomato. Note that post-TAM
tdTomato expression is solely controlled by the CAG promoter and Gt(RO- SA)26Sor
chromosomal locus (tdTomato reporter locus). (B) Permanent activation of tdTomato
expression in VEcad or Nestin-expressing cells was achieved by feeding adult mice
tamoxifen for 1.5 months. Mice were sacri- ficed at the indicated times, fixed and
histological assessment was performed.
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Table A1

Cell lineage tracing results for vascular endothelial cadherin and Nestin

Cell types were scored semi-quantitatively for the relative abundance of tdTomato positive
cells (+) at the indicated times following initiation of tamoxifen treatment in (A) VEcadCreERT2/Rosa-flox-STOP-tdTomato or (B) Nes-CreERT2/Rosa-flox-STOP-tdTomato
transgenic mice. Cell types without (–) tdTomato labeling are also shown. Notes: amyocytes
very weakly labeled with most signal surrounding the muscle fiber; babundant weakly
positive cells; cpossible tdTomato+ tumor noted; dweakly positive
Cell type
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postpostpostTAM
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TAM
A. Vascular endothelial cadherin cell lineage
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Cell type

1.5 mon 3 mon 6 mon
postpostpostTAM
TAM
TAM
A. Vascular endothelial cadherin cell lineage
tracing

Cell type

1.5 mon
postTAM

3 mon
postTAM
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postTAM

B. Nestin cell lineage tracing
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–
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–
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Central Nervous System
Examination of the central nervous system (CNS) following TAM treatment revealed
tdTomato-positive cells in several cell types not previously reported to share embryonic
origins with endothelial cells. Positive cellular projections were observed in the olfactory
bulb adjacent to but outside of glomeruli, suggesting that these cells are not olfactory neurons
(Figure A2). These projections were noted in a juxtaglomerular region within all levels of
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olfactory bulb sections and at all post-TAM treatment time points. No associated somas were
observed, suggesting that these projections originated outside of the olfactory bulb.

Figure A2
Vascular endothelial-cadherin cell fate mapping in the central nervous
system. Adult mice possessing VEcad-CreERT2/Rosa-flox-STOP-tdTomato were fed
tamoxifen-containing chow for 1.5 months and mice sacrificed at the indicated times
following initiation of treatment. Representative channel merged images from fixed and
Hoechst labeled tissues. Nuclei are labeled by Hoechst (blue) and cell lineage tracing is
indicated by tdTomato (red). The areas shown in micrographs are indicated by highlighted regions (red boxes) in diagrams to the right where the granule cell layer (GCL),
glomerular layer (GL), lateral ventricle (LV) and fourth ventricle (4V) are shown.
Arrowheads highlight labeled cells and cellular appendages (white scale bars: 400 μm).

Interestingly, numerous tdTomato+ cells were detected in the granule layer of the
cerebellum (Figure A2). Positive cellular projections within the molecular layer were
detected and confocal microscopic examination (Figure A3A, AS2, and AS4) confirmed that
the abundant positive cells in this region were cerebellar granule neurons (CGNs). A clear
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gradation of positive CGN expression was observed, with a peak at 3 months post-TAM
treatment and with complete absence observed at 6 months. The choroid plexus lining the
ventricle ventral to the cerebellum was tdTomato+ at all time points, with peak frequency of
tdTomato expression occurring 3 months following TAM treatment. The subventricular zone
(SVZ), a region possessing adult olfactory bulb neuronal progenitors, exhibited positive
labeling only in the ependymal layer (SVZ layer I) at 3 months of age (Figure A2).

Figure A3
Cerebellar granule neurons and hair follicle stem cells express vascular
endothelial-cadherin fate mapping reporter. Representative confocal microscopy images
from adult VEcad-CreERT2/ Rosa-flox-STOP-tdTomato transgenic mouse cerebellum
(A) and skin (B,C) at three months following the start of tamoxifen treatment.
Immunohis- tochemical labeling for (A) NeuN (green) or (B, C) K15 (green) with tdTomato (red) and nucleus (Hoechst; blue) are shown at two magnifications to demonstrate
the rare occurrence of K15-tdTomato colocalization. Images captured using a Zeiss
Laser Scanning Confocal Microscope Meta 510 sys- tem. Orthogonal projections
provided in the supplementary data indicate cells exhibiting (#) red/green
colocalization. Asterisks (*) signify cells with- out co-localization, hair shafts (HS) are
also shown.
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Hair follicle stem cells
Inspection of integumentary tissue obtained from the dorsal pelt of adult transgenic
mice revealed tdTomato expression within hair root tissue (Figure A4). The most robust
labeling was observed 1.5 months after TAM treatment, with labeling decreasing at 3 months
and reaching undetectable levels at 6 months. Confocal microscopic assessment (Figure3A-C
and AS2B–D) revealed that a small portion of tdTomato-expressing cells co-label with the
hair root stem cell marker K15. It is interesting to note the numerous instances in which
tdTomato-labeled cells were observed in close proximity to K15-expressing cells without
exhibiting co-localization (Figure AS2B–D).
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Figure A4
Vascular endothelial-cadherin cell fate mapping in the periphery. 4–5Month-old VEcad-CreERT2/Rosa-flox-STOP-tdTomato mice were provided tamoxifen
chow for 1.5 months and sacrificed at the times shown. Images were obtained from
fixed and Hoechst stained tissues. Cell lineage tracing is evidenced by tdTomato (red)
and nuclei are indicated by Hoechst (blue) labeling. Arrowheads highlight labeled cells
(white scale bar = 400 μm). Red boxes displayed in diagrams indicate region shown in
the associated micrographs. Asterisk (*) indicates tdTomato+ muscle fibers underlying
skin; Intestinal lumen (L) and tdTomato+ crypt cells (arrowheads) are labeled. Renal
tissue diagram indicates the location of the renal pelvis (R.P.).
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Skeletal muscle
The hamstrings of adult mice were also inspected for tdTomato labeling (Figures A4
and AS3). Surprisingly, extensive labeling was observed at 1.5 months, with maximum
labeling observed 3 months after TAM treatment. After 6 months, faint fluorescence was still
evident surrounding muscle fibers, indicating labeling within the endomysium region with
possible satellite cell involvement. No strongly labeled muscle fibers were observed for that
time point. Labeling was concentrated in localized regions of muscle whenever robust
tdTomato expression was observed (1.5 and 3 months post-TAM), leaving most areas of
muscle with no labeled fibers. In addition, muscle residing beneath the subcutaneous layer of
dorsal skin was found to be weakly tdTomato+ at 6 months post-TAM with no detectable
fluorescence at 1.5 or 3 months (Figure A4).
Pancreas
Another unexpected finding was the observed labeling of pancreatic islets (Figure
A4). There was a well-defined gradation of labeling, with all observed islets possessing
tdTomato-positive cells 1.5 months post-TAM and with 83% of islets containing one or more
positive cells 3 months post-TAM. No tdTomato+ cells were observed 6 months post-TAM.
Confocal microscopic analysis (Figures A5A and AS5A) revealed that some of the positive
cells were beta cells (3% insulin+). It is worthwhile to note the extremely close proximity of
the tdTomato-positive cells with insulin-positive cells in an interwoven configuration
(Figures A5A, B and AS5A, B). Co-labeling with glucagon (Figure A5C and Additional
Figure AS5C) was not observed, indicating that none of the tdTomato-expressing cells at
these time points were alpha cells.
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Figure A5
Vascular endothelial-cadherin fate mapping labels pancreatic βcells.Immunohistochemistry was performed for pancreatic insulin (A, B) and tdTomato
reporter expression at three months post-tamoxifen treatment in adult VEcadCreERT2/Rosa-flox-STOP-tdTomato transgenic mice. Representative images were
obtained by confocal microscopy for insulin (A, B; green), glucagon (C; green),
tdTomato (red) and the nu- cleus (Hoechst; blue). Two magnifications of separate fields
are shown to demonstrate the rare instances of Insulin-tdTomato colocalization. A
Zeiss Laser Scanning Confocal Microscope Meta 510 system was used to capture and
analyze the images shown. Confocal orthogonal projections presented in the
supplemental data section were utilized to confirm cells with (#) or without (*)
green/red co-localization

TdTomato labeling was also detected in the acini of the exocrine pancreas (Figures
A4 and AS6). The most robust labeling was observed at 1.5 months and decreasing
thereafter. Only a small minority of pancreatic acini exhibited positive labeling. Similar to
the pattern witnessed in skeletal muscle, positive cells were most often grouped in close
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proximity to each other. Likewise, only a very faint fluorescent signal in acini was detected 6
months post-TAM.
Renal Cells
Kidney sections were assessed and found to exhibit strong tdTomato expression 1.5
months after TAM administration (Figure A4). Labeling was restricted to the cortical layer
and markedly absent from the medulla. This suggests that tdTomato labeling was likely
confined to proximal and distal convoluted tubules. Expression intensity diminished
significantly 3 months post-TAM and was only very weakly detectable in the cortex at 6
months. It should be noted that residual urea would have been flushed from the tissue
sections by numerous washes associated with sample preparation before imaging. Therefore,
it is not expected that filtrate or urine (which might exhibit tdTomato fluorescence)
contributed to the observed signal.
Small Intestines
Examination of the intestinal tract revealed positive tdTomato labeling for crypt cells
(crypt of Lieberkühn) found in both the duodenum and ileum (Figure A4). These labeled
cells were concentrated within the most basal portion of the intestinal gland. The most
intense labeling was observed 1.5 months post-TAM and labeling was completely absent (or
very indistinct) 3 and 6 months following TAM treatment. No fluorescence was observed for
colonic cells at any time point.
Nestin Cell Lineage Tracing Labels for Canonical and Non-Canonical Targets in Adult Mice
The intermediate filament Nestin is known to exhibit a promiscuous expression
pattern. However, it has been reported that some endothelial cells (as well as specialized
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endothelial progenitor cells) express Nestin in adult mice (Mokrý et al., 2008; Suzuki et al.,
2010; Ding and Morrison, 2013; Itkin et al., 2016; Dusart et al., 2018). Therefore, Nestin cell
lineage tracing (Nes-CreERT2), as employed here (Figure A1), could provide additional
information with respect to endothelial cell progeny. We found both canonical Nestin cell
progeny as well as novel cell labeling events show some correlation with VE-cadherin cell
lineage tracing. A detailed summary of Nestin cell lineage tracing results can be found in
Table A1and additional image sets are provided in Additional file 1.
Central Nervous System
Analysis of adult mouse brain (Figure A6) showed tdTomato labeling of neurons in
the granule cell layer of the olfactory bulb at 3 months, which was maintained at a similar
level 6 months post-TAM. This is consistent with previous reports of Nestin-positive
progenitors migrating from the SVZ to establish adult-born olfactory bulb neurons (Altman,
1969; Menezes et al., 1995; Zerlin et al., 1995). Labeled olfactory neurons were not present
at 1.5 months, which indicates that the tdTomato-expressing cells at 3 months were indeed
derived outside of the olfactory bulb. Interestingly, we observed juxtaglomerular projections
in the olfactory bulb at all time points, as was witnessed in VE-cadherin lineage tracing
experiments described above. No associated cell somas were noted, which indicates that
these projections originated outside of the olfactory bulb. Similar to adult olfactory bulb
granule neurons, populations of hippocampal cells are known to undergo adult neurogenesis
from Nestin+ progenitors (Palmer et al., 1995). Supporting this notion, we find tdTomatopositive cells in the hippocampus beginning 3 months following TAM administration and
increasing at 6 months. Interestingly, we find only a relatively small number of labeled cells
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in this region, despite numerous reports in the literature of abundant neuronal regeneration in
the hippocampus of adult mice (Altman and Das, 1965; Bayer et al., 1982).

Figure A6
Nestin cell fate mapping in the central nervous system. Transgenic NesT2
CreER /Rosa-flox-STOP-tdTomato mice at 4–5 months of age were fed tamoxifen-lad- en
chow for 1.5 months and then sacrificed at thetimes shown post treatment initiation.
Channel merged images were then acquired from fixed and Hoechst stained tissues.
Nuclei are labeled by Hoechst (blue) and cell lineage tracing is indicated by tdTomato
(red). Images shown were obtained from the regions indicated by the red box in the associated diagram to the right where the granule cell layer (GCL), glomerular layer
(GL), lateral ventricle (LV) and fourth ventricle (4V) are shown. Arrow- heads highlight
labeled cells and cellular append- ages; # indicates autofluorescence from wrinkled
tissue region (white scale bars: 400 μm; green scale bars: 1000 μm).
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Our study also detected tdTomato-labeled cerebellar granule neurons at 3 and 6
months following treatment with TAM (Figure A6). No tdTomato-positive cells were noted
in the 1.5-month cohort. Both the 3- and 6-month groups exhibited far fewer positive
cerebellar granule neurons compared to our VE-cadherin study. Assessment of the nearby
choroid plexus showed sparse labeling at 1.5 and 6 months. Surprisingly, no labeled cells
were observed 3 months after TAM treatment for the cohort of mice we examined. This
correlates inversely with VE-cadherin labeling of the same structure at 3 months. Another
interesting finding was positive labeling of ependymal cells lining the ventricular surfaces
extending throughout the brain, which was absent at 1.5 months but robustly labeled 3 and 6
months post-TAM. The expression pattern also shows a clear disconnect between the choroid
plexus and the ubiquitous ependymal layer indicating differential regulation for their
production.
Skeletal Muscle
Investigation of skeletal muscle obtained from hamstring found tdTomato-labeled
muscle fibers 3 months after TAM treatment while being absent in the 1.5-month group
(Figure A7). However, the 6-month cohort showed positive labeling for very few muscle
fibers. It is evident that the majority of positive cells at 3 months have an elevated signal
originating from the endomysium area in addition to signals originating from myocytes.
Comparable to VE-cadherin tracing, Nestin-traced myocytes were found in close proximity
to each other. We also observed robust Nestin tracing to muscle underlying the subcutaneous
fat layer of dorsal skin at 3 and 6 months post-TAM but not at 1.5 months (Figure A7).

89

Figure A7
Nestin cell fate mapping in the periphery. Transgenic NesCreERT2/Rosa-flox-STOP-tdTomato mice at 4–5 months were fed tamoxifen-laden
chow and tissue har- vested at the indicated times following treatment initiation. The
representative merged channel images were acquired from tissues that were fixed and
Hoechst labeled. Cell lineage trac- ing is evidenced by tdTomato (red) and nuclei are
indicated by Hoechst (blue) labeling. Note in hair follicles at 1.5 months after tamoxifen
addition, the observed fluorescent signal is only found in hair shafts (no labeled cells).
Labeled hair folli- cle cells observed at 6 months post-tamoxifen were confirmed K15negative. Red boxes displayed in diagrams on the right indicate region shown in the
associated micrographs. Asterisk (*) indicates tdTomato+ muscle fibers underlying skin.
Arrow- heads highlight labeled cells and the ileal lumen (L) is indicat- ed [white scale
bar: 400 μm].
Small Intestine
Nestin cell lineage tracing revealed positive labeling for ileal crypt cells at 1.5 months and
absence at 3 and 6 months post-TAM treatment (Figure A7). Labeling was analogous to VEcadherin tracing for this tissue. Conversely, no labeling was observed for duodenal crypt
cells, suggesting divergent mechanisms for these two tissues. Interestingly, a small mass of
tdTomato-positive cells possessing irregular morphology (possible tumor) was noted in the
ileum of a 3 month post-TAM mouse (Additional file 1).
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Discussion
The non-endothelial tdTomato expression patterns observed in this study are likely due
to differentiation events traced from endothelial cells. This is supported by previous work
that examined the expression pattern of the VEcad-CreERT2 mouse line used in this study
(Monvoisin et al., 2006). Monvoisin et al. found that reporter gene expression by these mice
is confined to endothelial cells following a 5-day intraperitoneal injection regimen of 4‐
hydroxy‐tamoxifen (4‐OHT) when examined 7 days post-treatment. In addition, inspection of
hematopoietic bone marrow cells revealed that VEcad-CreERT2 mice exhibited very few
reporter positive cells (0.3%) compared to negative control mice (0.2%) suggesting only a
negligible contribution from these sources. This group also assessed skeletal muscle in adult
mice (6–8 weeks of age) following 3-day tamoxifen injection at 2 days, 1 week and 6 weeks
post-injection. No positive skeletal myocyte reporter expression, only endothelial cells (by
morphology), was noted for any time point. This is consistent with our finding of
tdTomato+ve skeletal muscle first appearing at 3 months post-treatment. It is important to
note that the reporter used by Monvoisin and colleagues to examine VEcad-CreERT2 mouse
line expression utilized a β-galactosidase cassette (activated by CRE activity) residing in
the ROSA26 locus and driven by native ROSA26 elements (Soriano, 1999). Our study utilizes
a flox-STOP-tdTomato reporter also residing in the ROSA26 locus (Madisen et al., 2010).
However, this reporter is driven by a CAG promoter that could exhibit differing expression
(cell type, intensity and silencing) properties. We observe endothelial cell expression
robustly in some tissues while it is markedly reduced in others. This could be due to
properties conveyed by the CAG promoter and a possibility that not all endothelial cells
exhibit the same expression profile in all tissues. Given the strong endothelial cell fidelity
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reported by Monvoisin et al. and numerous studies of VE-cadherin immunohistochemistry,
the VEcad-CreERT2 cassette portion of this dual transgenic system appears to be functioning
as intended.
The robust labeling of large numbers of cerebellar granule neurons by VE-cadherin
tracing was a notable finding. Unlike other regions of the brain, development of the
cerebellum begins postnatally, which may represent an alternative development strategy for
CGNs. It has been shown that despite elimination of canonical CGN precursors in the early
postnatal mouse brain by irradiation and genetic approaches, CGNs are nevertheless
generated at high levels (Wojcinski et al., 2017). Ponti et al. (2008) reported that cells
previously classified as astroglia and interneuron progenitors are in fact distinct from
neonatal canonical CGN progenitors and that in peripubertal rabbits they give rise to large
numbers of adult-produced CGNs. A separate group of researchers has also presented
evidence indicating that a Nestin-expressing progenitor pool is reprogrammed to contribute
to CGN repopulation following acute depletion in postnatal mice (Wojcinski et al., 2017).
Interestingly, we also observed Nestin+ progenitors tracing to CGNs. Our study suggests that
only a very small number of CGNs are regenerated (absent of injury) from a Nestinexpressing progenitor in adult mice. VE-cadherin+ progenitor cells contribute to the vast
majority of labeled CGNs, indicating at least two distinct pools of progenitor cells
(Nestin+ and VE-cadherin+) for the homeostasis of adult mouse cerebellum. These findings
suggest an opportunity to deliver gene therapy intravenously for direct effects on CGN
physiology.
Ependymal cells have been described as a source of CNS progenitor cells in the adult
brain (Johansson et al., 1999) in addition to performing other important homeostatic

92
functions such as cerebrospinal fluid production (Becht, 1920; Bruni et al., 1985). Here we
report that the ependymal layer is sparsely labeled by VE-cadherin tracing throughout
ventricular surfaces 3 months post-TAM (and including the choroid plexus just ventral to the
cerebellum). Ependymal labeling was only visible in the choroid plexus adjacent to the
cerebellum in the 1.5- and 6-month cohorts. We also observed intense Nestin tracing for the
ubiquitous ventricle-lining ependymal layer throughout the adult mouse brain. These results
suggest the possibility of a Nestin+/VE-cadherin+ choroid plexus progenitor in adult mice,
which is consistent with an endothelial subtype.
This study also revealed VE-cadherin tracing to hair follicle cells. Examination by
confocal microscopy revealed that a very small proportion of these cells were positive for a
hair follicle stem cell marker (K15). This is a surprising finding, given that hair follicle stem
cells are believed to be of mesenchymal origin. As such, K15+ stem cells would not be
expected to be derived from a progenitor that expresses an endothelial marker. The highest
level of labeling was observed 1.5 months post-TAM where most hair follicles had at least
one positive cell per section; significantly reduced labeling was observed at 3 months and
labeling was reduced to undetectable levels at 6 months. This implies a rapid turnover rate
consistent with hair growth in mice. Unlike VE-cadherin, Nestin did not trace to hair follicle
stem cells. We did, however, observe an enrichment of Nestin-traced hair follicle-associated
capillaries.
Inspection of skeletal muscle from hamstring showed VE-cadherin tracing at 1.5
months post-TAM treatment followed by a peak in tdTomato+ muscle fiber number at 3
months. No strongly positive myocytes were observed by 6 months and only faintly labeled
fibers remained. This suggests that the signal resulting from the fusion of VE-cadherin-traced
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progenitors with myocyte cytosol had been diluted out through fusion with non-labeled
progenitors after the 3 month post-TAM time point. We also observed Nestin tracing in
hamstring at 3 months post-TAM (no labeling in the 1.5- or 6-month cohorts). Additionally,
we found VE-cadherin and Nestin tracing to muscle underlying subcutaneous dorsal pelt.
This indicates the possible existence of a Nestin+ and VE-cadherin+ skeletal muscle
progenitor in adult mice. Previous investigations have reported the existence of skeletal
muscle satellite cells in adult animals termed myoendothelial cells that express endothelial
cell markers including VE-cadherin (Zheng et al., 2007). Whether these cells are of
endothelial origin remains to be determined. Supporting the notion of endothelial-skeletal
muscle transdifferentiation are reports of extravascular expression following intravenous
delivery of transgenes. A group reported that intravenous delivery of adeno-associated virus
(AAV9) containing CRISPR/CAS9 editing constructs, carried out in a canine model of
Duchenne muscular dystrophy (Amoasii et al., 2018), resulted in successful editing of a
mutant dystrophin gene in skeletal muscle. Interestingly, this group found an extremely high
percentage of successfully edited/transduced skeletal myocytes at 2 months post-systemic
AAV injection, even far surpassing what was observed in this study. Taken together, these
findings imply that intravenous delivery of gene therapy could be undertaken to correct a
defined mutation or provide a trophic factor to improve outcomes for skeletal muscle disease.
Investigation of VE-cadherin cell lineage tracing within the pancreas uncovered
tdTomato labeling of islets. All islets examined at 1.5 months post-TAM contained
tdTomato+ cells and 83% of islets at 3 months post-TAM displayed labeling. No labeling was
evident at 6 months, suggesting complete turnover of labeled cells by that time. Confocal
assessment confirmed that a small proportion (3%) of tdTomato+ islet cells were insulin-
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producing β cells. No tdTomato-expressing cells were found to be glucagon+ α-cells. The
presence of VE-cadherin-traced β cells suggests the possible existence of a β cell precursor
cell in adult mice with endothelial origins. The evident decrease in tdTomato+ islet cells over
time provides support for the existence of regenerative mechanisms of β cells in adult mice,
which is currently a subject of controversy (Yu et al., 2016). The existence of a natural
endothelial-derived β cell progenitor could offer new intravenous therapy options for
prolonged treatment of diabetes. In addition, this knowledge could inform strategies to
stimulate β cell regeneration in vivo.
Exocrine pancreatic acini were also found to contain tdTomato-labeled cells
following VE-cadherin tracing. Only a few acini lobes per section exhibited the fluorescent
marker, though when present, positive cells were grouped in close proximity. The highest
abundance of labeled acini was found 1.5 months post-TAM, which decreased markedly 3
months after treatment. The 6-month group showed only rare and individual
tdTomato+ acinar cells. This labeling pattern suggests the existence of an endothelial-derived
progenitor and that near-complete regeneration of acini cells occurred over this 6-month
period.
Renal tissue was also found to exhibit VE-cadherin tracing. Specifically, cells
comprising the convoluted tubules within the renal cortex had pronounced labeling at 1.5
months post-TAM, with a gradual loss observed at 3 months and only a very faint signal
detected at 6 months. The progenitor source for adult proximal convoluted tubule cells is still
highly debated and our finding adds to a substantial body of evidence regarding extra-renal
and atypical sources (Poulsom et al., 2001; Gupta et al., 2002; Sugimoto et al., 2006;
Castrop, 2019). The observed fluorescent signal in this study likely does not arise from
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filtrate since the tissues were thoroughly flushed during multiple washes following sectioning
onto slides. In addition, tdTomato labeling is completely absent from the renal medulla,
excluding fluorescence contributed directly by filtrate cells in the loop of Henle or medullar
collecting tubules. However, it cannot be ruled out that label-positive proximal convoluted
tubule cells obtained tdTomato from early filtrate via their native protein-recovery
mechanisms and thereby obtained cytosolic fluorescence independent of a
transdifferentiation event. An alternative interpretation of this result could be that cell fusion
events of proximal convoluted tubule cells with other tdTomato+ cells decreased and that
contributed cytoplasm was gradually turned over (similar to myocytes). Another possibility is
that the weak signal at 6 months is due to activation of CRE by tamoxifen that has persisted.
Further studies are needed to explore these possibilities as the prospect for renewal of these
important cell types could be useful in the development of therapeutic strategies for the
treatment of kidney disease.
Our assessment of the digestive tract revealed VE-cadherin cell lineage tracing of
duodenal and ileal gland crypts. Labeling was confined to the base of the intestinal crypts and
was robust at 1.5 months but disappeared 3 months after TAM treatment began. This
suggests a rapid turnover of these cells, which is consistent with that of cells found within a
highly proliferative epithelial tissue. A weaker fluorescent signal was observed for more
mature cells emanating from the crypts that form the intestinal villi. Interestingly, we did not
observe any tdTomato labeling within colonic crypts, which suggests a different etiology in
adult mice. We also found that Nestin traced to Ileal crypts at 1.5 months post-TAM (and
disappeared by 3 months) but did not trace to the duodenum suggesting divergent origins for
these adult tissues.
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Conclusion
There is evidence of tissue homeostasis by actively dividing stem cells and one or
more pools of quiescent stem cells working in concert to maintain cell replacement needs (Li
and Clevers, 2010; Blanpain and Fuchs, 2014). In such cases, it is possible that the selector of
the donating quiescent progenitor is the tissue environment rather than the cell type
classification of the progenitor itself. For example, a growing body of evidence indicates that
some quiescent brain regions possess the ability to foster the differentiation of transplanted
progenitor cells from varied sources into functional neurons (Lindvall et al., 1989; Volkman
and Offen, 2017). Moreover, experimental ablation of one type of progenitor can cause
restoration by another type (Rompolas et al., 2013; Blanpain and Fuchs, 2014). If indeed this
form of plasticity occurs broadly in adult mammals, endothelial cells would represent the
most readily available cell type for “recruitment” as a progenitor across tissues. Evidence
presented in this study supports the notion of an endothelial population that
transdifferentiates into other embryonically distinct cell types and which is also a substantial
contributor to adult mammalian tissue homeostasis. Confirmation of such a finding would
offer new insights into the pathology of human disease and present potential therapeutic
avenues.
Limitations of the CreERT2/Rosa-floxed-STOP-tdTomato System
•

a) Cell fusion events cannot be completely ruled out. However, Hoechst labeling of
nuclei did not reveal any multinucleated cells (with the exception of myocytes) by
conventional or confocal microscopy. In addition, previous studies involving bone
marrow-derived stem cell transplantation (Alvarez-Dolado et al., 2003) did not reveal
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cell fusion events for any of the tdTomato+ cells observed in this study, indicating
that tdTomato-expressing cells are likely not derived from fusion events with
hematopoietic cells (e.g., B-cells).
•

b)The genomic location (Rosa26) of the reporter cassette, in concert with the
exogenous promoter employed (CAG promoter-driven-tdTomato), dictates the celltype expression pattern of tdTomato following the initial activation from flox-STOP
removal by CreERT2. Therefore, genomic editing by activated CreERT2 may have
occurred in a given cell without the production of a fluorescent signal if
the Rosa26 locus or CAG promoter is silenced by that cell type.

•

c) CRE activity can result in two outcomes. Correct editing creates a tdTomato
sequence with the removal of a stop-codon-containing cassette and the subsequent
expression of a functional fluorescent reporter. However, CRE activity can also result
in translocation of cut DNA fragments to other locations in the genome or other
rearrangements that do not produce a functional reporter. In these instances, cell
lineage tracing mechanisms would be activated but not observed.

•

d) Promoter silencing is a reported cellular response to numerous constitutive
promoter systems (e.g., CMV, CAG) (Choi et al., 2005; Xia et al., 2007; Herbst et al.,
2012). Reporter gene silencing could also confound the disappearance of the
tdTomato signal at later time points. Other approaches would be necessary to
determine if a loss in signal is due to cell turnover or CAG promoter silencing.

•

e) The observation of fewer reported tracing events could be the result of cell death.
Double-stranded cuts directed by CRE in target cells initiate DNA repair systems. If
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repairs are not made correctly or in a timely fashion, cells are susceptible to
apoptosis. In addition, cell death could be directed by the immune system against
tdTomato-derived peptides presented in MHC class I complexes. However, this
prospect is unlikely, given that tdTomato is observed in some tissues in both VEcadherin and Nestin mouse lines at 6 months post-TAM.
•

f) Contributions by extracellular vesicles emitted from tdTomato-expressing cells
cannot be determined in this system. It is possible that extracellular vesicles
containing tdTomato are released by edited/labeled cells and accumulated in target
cells, thereby leading to fluorescence in the target cell that is not associated with a
transdifferentiation event. This is an inherent limitation of the Rosa-floxed-STOPtdTomato system.
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Additional Figures

Figure AS1. Prototypical arterial endothelila cell expression of dTomato following
VE-cadherin cell-lineage tracing in real tissue. Renal tissue was harvested from VEcadCreERT2/Rosa-flox-STOP-tdTomato transgenic mice 1.5 months post-tamoxifen
treatment initiation. Tissue samples were fixed, cryosectioned (15 µm) onto slides,
stained with Hoechst dye (nuclear label) and then mounted with coverslips. The
displayed image was captured by an EVOS M7000 conventional fluorescence
microscopy system. The merged image shows tdTomato (red) and Hoechst (blue)
channels. Arrowhead indicates tdTomato+ endothelial cells of the internal elastic
lamina of a renal glomerulus arteriole. Asterisks (*) show tdTomato+ convoluted
tubules also present in this micrograph.
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Figure AS2. Confocal microscopy orthogonal analysis of VE-cadherin-traced
cerebellar granule neurons and hair follicle cells presented in Figure A3. (A) NeuN
(green) /tdTomato (red) co-labeling (arrowheads) by IHC confirmed for cerebellar
granule neurons through orthogonal reconstruction from confocal image stacks. (B, C)
Rare hair follicular cells exhibit K15 (green)/tdTomato (red) co-localization
(arrowheads). (D) The vast majority of tdTomato hair follicle cells do not exhibit colabeling with K15 (green) despite often being in very close proximity. Images captured
using a Zeiss Laser Scanning Confocal Microscope Meta 510 system.
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Figure AS3. Examination of skeletal myocytes following VE-cadherin cell lineage
tracing high resolution confocal image. Hamstring tissue was harvested from VEcadCreERT2/Rosa-flox-STOP-tdTomato transgenic mice 3 months post-tamoxifen treatment
initiation. Fixed samples were sectioned (15 μm) onto slides, labeled with Hoechst dye,
mounted with coverslips, and imaged using an Olympus FV3000 Laser Scanning
Confocal Microscope system. The displayed image was obtained from a series of 10 μm
z-stacked planes compressed into a maximum intensity projection image showing
tdTomato (red) and Hoechst (blue) channels.
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Figure AS4. VE-cadherin-traced cerebellar granule neurons confocal microscopy high
resolution tiled image.Tissue was harvested from VEcad-CreERT2/Rosa-flox-STOPtdTomato transgenic mice 3 months post-tamoxifen treatment initiation. The
cryosectioned tissue (15 μm) was fixed, labeled with Hoechst dye, and mounted with a
coverslip. A tiled image was captured for 10 μm z-stacked planes and stitched using a
Zeiss 880 Airy Scan system. Hoechst dye (blue) and tdTomato (red) channels are
displayed in the maximum intensity projection image shown.
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Figure AS5 Confocal microscopy orthogonal analysis of VE-cadherin-traced
pancreatic islet cells presented in Figure A5. (A) Immunohistochemistry for
insulin/tdTomato-co-labeled cell (arrowhead) assessed by orthogonal reconstruction
from confocal stacked images. (B) Almost all tdTomato positive islet cells examined are
insulin (green)-negative despite very close physical proximity. (C) No glucagon
(green)/tdTomato co-labeled cells were observed in any pancreatic section examined.
Arrowheads indicate a point of assessment. A Zeiss Laser Scanning Confocal
Microscope Meta 510 system was used to capture and analyze the images shown.
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Figure AS6 VE-cadherin cell lineage tracing high-resolution confocal image of
pancreatic acini.Pancreatic tissue was harvested from VEcad-CreERT2/Rosa-flox-STOPtdTomato transgenic mice 3 months post-tamoxifen treatment initiation. Tissue samples
were fixed, cryosectioned (15 μm) onto slides, stained with Hoechst dye and then
mounted with coverslips. The displayed image was captured by an Olympus FV3000
Laser Scanning Confocal Microscope system from 10 μm z-stacked planes and
represented as a maximum intensity projection. The merged image shows tdTomato
(red) and Hoechst (blue) channels.
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Abstract
Drug development is a complicated, slow and expensive process with high failure
rates. One strategy to mitigate these factors is to recycle existing drugs that have viable
safety profiles and have gained Food and Drug Administration approval following
extensive clinical trials. Cardiovascular and neurodegenerative diseases are quite difficult
to treat, and there exist few effective therapeutics, necessitating the development of new,
more efficacious drugs. Recent scientific studies have led to mechanistic understanding
of heart and brain disease progression, which has led researchers to assess myriad drugs
for their potential as pharmacological treatments for these ailments. The focus of this
review is to survey strategies for selection of drug repurposing candidates and provide
representative case studies where drug repurposing was used to discover therapeutics for
cardiovascular and neurodegenerative disorders, wherein anti-inflammatory drugs have
profound side-effects during chronic use and therefore new alternatives are needed.
Introduction
Drug development is a long, labor-intensive process with no guarantee of success.
On average, it takes 10 years and 2.6 billion dollars to develop a new drug, with success
rates averaging only about 12% [1]. One way to mitigate the barriers of drug
development is to repurpose Food and Drug Administration (FDA) approved drugs for
the treatment of different diseases. Drug repurposing is the practice of finding new uses
for existing drugs at any stage of development. The benefit of drug repurposing is that the
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risk of failure is significantly lower than drug development, which permits more effective
use of resources to optimize drug efficacy for treatment of the desired ailment. Much of
the primary research regarding repurposed drug safety, mechanism and dosage has
already been completed at the time the drug was first studied [2]. For example, a drug
that demonstrated efficacy in animal models with low side effects but failed in human
clinical trials to perform its intended purpose, may be a good candidate for use as a
therapeutic for a different disease. Drugs with potential to be repurposed have progressed
through many of the steps required to meet regulatory safety and potency benchmarks,
allowing for an accelerated and abbreviated path toFDA approval. A few representative
examples of successful drugs that have been repurposed include amantadine, aspirin,
mecamylamine, minoxidil and tamoxifen (Table B1) [3]. Repurposed drugs are generally
screened by computer search algorithm from databases of therapeutics that may or may
not have been sufficiently effective in providing treatment for the pathology that served
as their original target. For example, some drugs lack sufficient drug-like qualities to
warrant further investigation for treatment of an intended illness, but modification of the
molecular scaffold or functional groups attached to the drug template may afford
attributes and activity suitable for therapeutic viability. The therapeutic index for a
repurposed drug requires investigation into dosage recommendations for maximal benefit
to counter the illness, while minimizing detrimental side-effects to the patient.
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Table B1.

Examples of repurposed drugs

Drug
Amantadine

Original purpose
Parkinson’s disease

Reference
[4,5]

Mecamylamine

Inflammation, pain
relief
Hypertension

Repurposed use
Influenza A,
COVID-19
(hypothesized)
Anti-platelet

Aspirin

Tourette’s syndrome

[7]

Minoxidil

Hypertension

Hair loss

[8]

Tamoxifen

Cancer

Leishmaniasis

[9]

[6]

Technology to repurpose drugs
Computational strategies for determining potential drug repurposing candidates
are a great starting place for researchers to find drugs that have previously been on the
market to take to new clinical trials. Multiple computational strategies have emerged to
identify potential candidates for drug repurposing. Of these, four strategies have gained
popularity in recent years and will be discussed in brief. These strategies are side effect
similarity mapping, genome-wide association studies (GWAS), small-molecule peptideinfluenced drug repurposing (SPIDR), and computational high throughput screening
(HTS) screening [10,11].
In side-effect similarity mapping, existing drugs are categorized by their side
effects using the Unified Medical Language System (UMLS) ontology for medical
symptoms. Developed by Campillos et al. (2008), 746 marketed drugs were organized
according to their listed phenotypic side effect similarities rather than a chemical
similarity, and 20 of these marketed drugs were confirmed through in vitro assays to
indicate that side effect similarity may be indicative of common protein targets. Using
this strategy, prediction of the likelihood that two drugs had the same target based on
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their side effects was demonstrated [12]. This study describes a process by which drugs
marketed for different targets could be identified as having potential for repurposing.
GWAS identify single nucleotide polymorphisms (SNPs) and their associated
phenotypes for individuals with a given disease. GWAS is performed by genotyping
individuals which share a common disease and determining whether a genetic variant is
shared to statistical significance among this population. Experimental validation by
chromatin precipitation is then performed and variants associated by phenotypic effects
[13]. This technique has been used to identify many novel variant to trait associations in a
wide variety of diseases such as macular degeneration, anorexia nervosa, depression,
coronary artery disease and diabetes mellitus, and can be used to determine novel drug
targets as well [14]. For example, GWAS have been used to identify SNPs for
Parkinson’s disease (PD) and determined that estradiol may protect dopaminergic
neurons in PD. This supported previous evidence that estradiol may be protective against
PD because men are more likely to be diagnosed [15]. The neuroprotective role of
estradiol was later confirmed in in vivo studies. At present, estradiol is still not an
approved treatment for PD, but efficacy studies are ongoing [2,16,17]. Another example
of GWAS being useful for determining novel drug targets was the identification of a gene
encoding a disintegrin and metalloproteinase with thrombospondin motifs TS7
(ADAMTS7), a gene implicated in coronary artery disease (CAD) for its presence
in angiographic CAD patients and role in smooth muscle cell migration, a finding that
supports the idea of genetically inherited CAD [18,19]. Using GWAS, it is possible to
identify new potential targets based on SNPs.
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SPIDR is a recently developed computational screening technique to identify
drugs that can target a specific receptor by looking at its peptide ligand conformational
space [20]. This method was integrated into the free program DockoMatic v 2.1, making
this process accessible to lower resourced institutions [21]. This technique works by first
utilizing the genetic algorithm managed peptide mutant screening (GAMPMS) to screen
for peptide mutants with high binding affinity to the receptor, and then this population of
peptides is moved over to the SimSearcher utility to search for the top small molecules
analogous to the peptide population for binding to the isoform [20]. SPIDR was
developed and used to find 12 small molecules computationally predicted to bind with
high affinity to a nicotinic acetylcholine receptor (nAChR) isoform associated with
Alzheimer’s and PD, by looking at alpha conotoxin MII peptide analogs that would bind
favorable to the receptor isoform specifically [20]. Following this publication, a
qualitative assay to detect dopamine release by ligand action on nAChRs was developed
with the intent to assess bioactivity of molecules that may act on different nAChR
isoforms for drug development. This assay was developed using luminescence-based
assay and validated with known nAChR binders acetylcholine, nicotine and cytisine [22].
This assay is intended to be used to test the small molecules found in the SPIDR
development publication for nAChR activity as an in vitro validation for the SPIDR
methodology.
Additionally, small molecule compound screens can be used to identify drugs
amenable to being repurposed. Computational programs such as AutoDock Vina are
often used to screen molecular library databases like ZINC, chEMBL, pubchem,
DrugBank, Chem Spider, and others [23]. Computational screens, in silico, are an ideal
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starting point for any drug discovery project to narrow down a list of molecules that may
bind your target with high affinity. However, wet lab experimentation needs to be
conducted, which can be done with commercially available libraries of drugs using in
vitro cell-based assays. Researchers study whether a drug being tested induces a
phenotypic effect in cell-based assays, which are usually performed in cell culture or on a
model organism whereas a target-based screen can be performed in vitro using techniques
like ELISA, Surface Plasmon Resonance (SPR) or Nuclear Magnetic Resonance (NMR)
spectroscopy. In this article we will briefly discuss strategies for repurposing drugs and
examples of drugs that are being repurposed for treatment of cardiovascular disease and
neurodegenerative disorders. Specifically, we will cover those conditions that affect both
cardiovascular and neurodegenerative disease such as inflammatory pathways, as these
conditions connect heart and brain disease.
Heart and brain interconnectedness in disease
There are currently few therapeutics for cardiovascular and neurodegenerative
diseases that provide suitable efficacy and minimal side effects, creating ideal conditions
for drug repurposing. Not only are cardiovascular and neurodegenerative diseases
difficult to treat, but treatment options remain limited, and many drugs do not cease
progression nor achieve remission of the disease state. Considerable progress has been
made in recent years to understand the molecular determinants of cardiovascular disease,
which encompasses a wide variety of disorders such as endothelial dysfunction,
atherosclerosis and pulmonary arterial hypertension, and neurodegenerative disorders,
such as Parkinson’s and Alzheimer's [24,25] Cardiovascular disease and
neurodegenerative disorders share a common trait in that inflammation is a component to
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the pathogenic process. Targeting inflammatory processes with repurposed drugs can
have a multitude of beneficial effects for patients with diseases of both the heart and
brain. Currently, repurposed drugs are being used in studies associated with two
cardiovascular related diseases that include endothelial dysfunction and pulmonary
arterial hypertension. As for neurodegenerative diseases, repurposed drugs are being
studied for the treatment of autophagy and neuroinflammation.
Targeting endothelial dysfunction in cardiovascular disease
Cardiovascular diseases including atherosclerosis, coronary artery disease and
arrhythmias that eventually lead to myocardial infarction and/or stroke. Ischemic events
such as these are the leading cause of death in the world [26]. Pharmacological
intervention of cardiovascular diseases is provided by statins, beta-blockers, and
angiotensin converting enzyme inhibitors. In more advanced cases, surgical intervention
may be necessary. The medications for cardiovascular disease target high cholesterol and
low-density lipoprotein levels, and hypertension. There is an emerging field of research
to discover small molecule inhibitors for alternative pathways aimed at the disruption of
heart disease progression [27]. There is a robust market for pharmaceutical companies to
synthesize drugs to treat disorders, but the potential for repurposing already FDAapproved drugs constitutes a desirable alternative to discovery since these medications
have been deemed safe enough for patient use and thus make clinical trials for novel use
non-trivial.
The endothelium is characterized by the cells of the tissue lining the various
organs of the body, including the arteries and lymphatic system. The endothelium plays a
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major role in blood flow and constriction by facilitating the synthesis and degradation of
vasodilating factors, such as nitric oxide (NO), arachidonic acid metabolites and reactive
oxygen species (ROS) [28]. Endothelial dysfunction occurs when the endothelium fails to
function properly. Namely, that the endothelium dysfunctions in the formation of
vasodilating factors. Endothelial dysfunction is especially important in cardiovascular
disease because it is a leading contributor to cardiac events. Endothelial dysfunction is a
component of atherosclerosis, which is characterized by the hardening and narrowing of
the arterial walls, and hyperlipidemia, or high lipid concentrations in the blood.
Three drugs investigated for their potential to treat diseases of endothelial
dysfunction that will be discussed here include colchicine, which has been traditionally
used to treat gout, methotrexate, an immunosuppressant and chemotherapy drug, and
Tocilizumab (brand name Actrema), an immunosuppressant used to treat severe
rheumatoid arthritis.
Colchicine
Colchicine is a secondary metabolite from the plants Gloriosa superba and
Colchicum autumnale, that is known to be toxic when ingested [29]. Its current approved
use is to treat gout, an inflammatory form of arthritis common in people with high levels
of uric acid in their blood. Due to its anti-inflammatory properties, colchicine is currently
under investigation as a potential endothelial dysfunction drug. Endothelial dysfunction is
a characteristic of cardiovascular disease that leads to an increase in macrophages, T
lymphocytes and growth factors that contribute to atherosclerotic lesion formation
associated with atherosclerosis [30–33]. The same inflammation inhibition mechanism
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that permits colchicine to be effective against gout, may also be applicable to the
treatment of patients with early stages of atherosclerosis [34,35].
Colchicine prevents inflammation by binding to tubulin, preventing tubulin
polymerization and function (see Figure B1) [18]. As a result, colchicine halts mitotic
cells in metaphase. Colchicine also concentrates in neutrophils and prevents chemotaxis
via the release of crystal-derived chemotactic factor, and inhibits monosodium urate
induced loss of myeloid inhibitory C-type lectin-like receptor in neutrophils and
interleukin-8 formation [36] Myeloid inhibitory C-type lectin-like receptor and
interleukin-8 are important in immune homeostasis and inflammatory response [37,38].

Figure B1.
Inhibitory pathway of colchicine.Colchicine inhibits activation of
purinergic P2X2/P2X7 receptors and blocks cation uptake and subsequent proinflammatory signaling cascades without affecting cell death. Colchicine also
inhibits the NALP3 inflammasome pathway, the Rho/ROCK pathway via
cytoskeleton rearrangement, and inhibits release of ROS, NO and TNFa. Figure 1
was created using BioRender.com (adapted from [36] .
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Cell adhesion is the process by which cells adhere to one another through the
action of proteins, electrostatic interactions, and hydrophobic interactions. Adhesion is
important because cells can use physical contact with one another to communicate via
signal transduction. Colchicine interferes with cell adhesion by inducing the shedding of
neutrophil adhesion molecules, which are important in neutrophil function [36]. These
neutrophil adhesion molecules include selectins and counter receptors which partake in
signal transduction. Selectins are single-chain transmembrane glycoproteins organized by
leukocyte (L), endothelial (E) and platelet/endothelial (P) selectins. They are
characterized by their similar homology in both sequence, structure and sugar ligands.
Colchicine reduces endothelial expression of selectins by acting on leukocytes in
coronary artery disease [35].
Nidorf et al. reviewed ongoing clinical trial results and experimental evidence that
supported the use of colchicine as an anti-inflammatory drug with promising efficacy
toward the treatment of atherosclerosis [34]. First, they describe the mechanisms by
which colchicine acts on the various inflammatory pathways including the production of
pro-inflammatory cytokines, such as interleukin (IL)-1ß, reduction of platelet leukocyte
interactions that lead to atherothrombosis and suppressing the growth of fibroblasts and
osteophytes. At lower doses, colchicine was found to have no reported side effects on
patients with liver and/or kidney disease [34]. The authors concluded that colchicine
could be repurposed for treatment of inflammation associated with atherosclerosis.
Methotrexate
Aminopterin, a precursor drug to methotrexate, has been used to treat childhood
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leukemia, dating back to the late 1940’s and early 1950’s. It was noted that the drug
interfered with connective tissue proliferation in patients undergoing leukemia treatment,
which led to studies into the effect of aminopterin on rheumatic disease [39]. A study in
1951 by Gubner et al. demonstrated that aminopterin was effective in alleviating signs
and symptoms of the disease associated with rheumatoid arthritis, psoriasis and psoriatic
arthritis. The synthesis of aminopterin proved to be a barrier to drug studies, inspiring
creation of methotrexate, which was easier to synthesize, but equally as efficacious as
aminopterin (Figure B2). In the 1960’s, the National Institute of Health reported that
methotrexate was effective at treating rheumatoid arthritis and psoriatic arthritis.
However, the rheumatologist community at the time maintained a fidelity for
corticosteroids to treat rheumatic syndromes, which stifled the use of methotrexate.
Further, and larger studies were conducted that established irrefutable evidence that
methotrexate was effective in the treatment of rheumatoid arthritis [40].
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Methotrexate is a synthetic disease-modifying anti-rheumatic drug that is a
structural analog of folic acid [25]. Methotrexate was originally used as a cancer drug but
has recently been investigated for its use in inflammation associated with endothelial
dysfunction. In a study of 673 patients, methotrexate was used for the treatment of
rheumatoid arthritis, and was determined that under proper dosing and use, it could be a
beneficial drug to treat arthritis with 1.7% adverse side effect frequency and 0.15%
mortality [41]. Methotrexate was identified as a good candidate for use to treat
inflammatory diseases, including endothelial dysfunction.
Methotrexate exerts a multitude of biochemical and biological perturbations when
administered to patients. While the exact or primary mechanism of action is not
completely understood, multiple modes of activity have been characterized that reveal
how methotrexate functions (Figure B3). First, methotrexate diminishes the immune
response by increasing the rate of T cell apoptosis. Methotrexate binds dihydrofolate
reductase, causing an increase in nitric oxide synthase uncoupling through the prevention
of the conversion of dihydrobiopterin to tetrahydrobiopterin (FigureB3a). Second,
methotrexate suppresses inflammation and the immune response by promoting the release
of adenosine. Metabolites of methotrexate inhibit aminoimidazole-4-carboxamide
ribonucleotide (AICAR) transformylase, causing an increase in the concentration of
intracellular AICAR and thus more adenosine release (Figure B3b). Third, methotrexate
increases the expression of long intergenic non-coding RNA p21, a mediator and
regulator of a variety of pro-apoptotic processes (Figure B3c) [42].
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Figure B3. Metabolic pathways of methotrexate. a) Methotrexate inhibits
dihydrofolate reductase (DHFR) and prevents conversion of dihydrobiopterin (BH2)
to tetrahydrobiopterin (BH4), leading to uncoupling of NO synthase. b)
Methotrexate inhibits AICAR transformylase, leading to increased adenosine levels
and subsequent anti-inflammatory responses. c) Methotrexate stimulates lincRNAp21 expression, leading to increased apoptotic gene expression and subsequent antiinflammatory responses.

There is increasing evidence that the 5′-adenosine monophosphate-activated
protein kinase (AMPK) is beneficial to the endothelium by protecting against apoptosis,
oxidative stress and increases NO production in the endothelium, which reduces
cholesterol efflux activity [25]. Stimulation of AMPK as a treatment for endothelial
dysfunction is under investigation. One study showed that application of methotrexate on
perivascular adipose tissue from Sprague-Dawley rats increased AMPK activity under
basal and inflammatory conditions when treated with a negative control, palmitic acid
[25]. A positive control using aminoimidazole-4-carboxamide ribonucleotide, a known
AMPK agonist, was also able to stimulate AMPK activity [25]. This study similarly
showed that methotrexate stimulated adiponectin mRNA expression and suppressed the
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pro-inflammatory molecules nuclear factor kappa B (NFκB) p-65, tumor necrosis factor
alpha (TNF-α), and interleukin-6 (IL-6) activity [25]. At the time of this review, only
studies of methotrexate on perivascular adipose tissue taken from sacrificed mice and in
vitro studies in cell culture have been performed, necessitating investigation into more
physiologically relevant in vivo model systems.
Contrarily, other studies have indicated that methotrexate may contribute to
vascular endothelial dysfunction by causing endothelial damage [43]. Methotrexate is a
direct competitor with folic acid for the active site of human serum albumin, and indeed
folic acid supplements are often provided in conjunction with methotrexate to prevent
folic acid deficiency [44]. A study performed in Wistar rats, by Sankrityayan in 2016,
showed that when administered with methotrexate, ex vivo vascular reactivity in the aorta
was significantly reduced [43]. Vascular reactivity is the phenomenon responsible for
both vasoconstriction and vasodilation, and those responses to various stimuli implicated
in vasculature. Methotrexate has also been implicated in the reduction of NO, leading to
increased oxidative stress and hindering of bioavailability of tetrahydrobiopterin by
oxidizing it to dihydrobiopterin in the aorta [45,46]. This leads to hypertension,
hyperlipidemia and induces endothelial dysfunction, because tetrahydrobiopterin is
necessary as a cofactor required for synthesis of NO [47].
There is contradicting evidence for methotrexate use as an endothelial dysfunction
drug. On one hand, there is data that suggests methotrexate reduces inflammation, while
on the other hand, methotrexate appears to lead to endothelial dysfunction. Therefore,
more studies must be performed to determine the true mechanism of action for
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methotrexate on the vascular endothelium if it is to be used to treat endothelial
dysfunction. There are currently 2140 clinical trials listed under the National Library of
Medicine’s clinical trial database with methotrexate being evaluated for treatment of
everything from ectopic pregnancy, to schizophrenia, to alopecia, and cancer. It appears
that in many pathologies where inflammation is a principal concern, or where
immunomodulation is of utility, methotrexate may provide benefit.
Tocilizumab
Tocilizumab (TCZ) is an IL-6 inhibitor and recombinant monoclonal antibody
used in rheumatoid arthritis treatment since obtaining FDA approval in 2010 [48]. TCZ
binds IL-6 and blocks JAK/STAT signaling to prevent the production of proinflammatory molecules [48,49]. It is currently being investigated for the treatment of
endothelial dysfunction due to its anti-inflammatory properties. This is because RA is
often listed as a co-morbidity in approximately 39-50% of atherosclerosis-related deaths,
with endothelial dysfunction presented in many RA patients [50]. One hypothesis is that
the release of networks of chromatin and granules (NETs) into the extracellular space, a
common occurrence in both RA and endothelial function. TCZ was found to alleviate
symptoms in endothelial dysfunction in a human clinical study [49].
Targeting pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a relatively rare condition, affecting
approximately 10-52 people per million population, characterized by the narrowing of the
pulmonary arteries [51,52]. Left untreated, pulmonary arterial hypertension leads to the
buildup of pressure on the right side of the heart when blood vessels in the lungs are
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diseased, causing the arteries to become increasingly narrow with time, and right-sided
heart failure, often resulting in premature death [53,54]. While the direct cause of
pulmonary arterial hypertension is unknown, a set of factors including liver disease, HIV
infection, intravenous drug use, autoimmune disorders, and others are suspected to be
culpable. For pulmonary arterial hypertension, there are several drugs under investigation
for use in PAH in clinical trials and are discussed in detail [55]. Of these, two drugs,
Anakinra and Ubenimex, target inflammatory processes specifically.
Anakinra
Anakinra was approved for use in rheumatoid arthritis by the FDA in 2001.
Anakinra is currently under investigation and has undergone Phase I clinical trial studies
for novel use in PAH [55,56]. Anakinra, an interleukin-1 (IL-1) receptor protein
antagonist analogue, is recombinantly expressed in E. coli and is administered via
subcutaneous injection. The proposed mechanism of action for PAH, done in mice, is
such that anakinra blocks perivascular macrophage recruitment in pulmonary artery
smooth muscle cells [57]. In an inflammatory response pathway, IL-1b binds to IL-1
receptor (IL-1R) and recruits the myeloid differentiation primary response protein 88
(MyD88) and induces IL-1 synthesis via NFκB activation. In this study, the goal was to
investigate whether this pathway played a role in the progression of PAH.57 First, it was
determined that in both the lung tissue taken of patients with PAH as well as mice with
PAH, there were increased expression levels of both IL-1R and MyD88. In IL-1R-/- and
MyD88-/- mice, severity of PAH was not significantly different between the two but
were significantly lower in severity than hypoxic wild-type mice. Hypoxic wild-type
mice treated with anakinra (20 mg/kg per day) were shown to have lower severity in
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PAH symptoms, namely, right ventricular systolic presser and hypertrophy, than
untreated mice. It was also observed than in both IL-1R-/- and MyD88-/- hypoxic mice as
well as wild-type mice treated with anakinra, there was no significant fold change in IL1b levels when compared to wild-type untreated mice with hypoxia over 48 hours. These
findings suggest that anakinra is a good potential treatment for PAH in that IL-1b is not
having to be expressed as an emergency measure for PAH. Furthermore, the pilot Phase I
clinical study (clinicaltrials.gov: NCT03057028) done with treatment of PAH by
anakinra found promising results by inducing IL-1 blockade.
Ubenimex
Ubenimex, also known as bestatin, is not currently approved for use by the FDA
for any disease; however, it has undergone Phase II clinical trials for potential treatment
of PAH [55]. Its original usage was for leukemia [58]. Ubenimex is a leukotriene A4
hydrolase (LTA4H) inhibitor, thought to block leukotriene B4 formation, thought to be
involved in PAH pathogenesis via pulmonary artery smooth muscle cell proliferation
[55,59]. However, results from the Phase II clinical trial are as yet unpublished.
Modulating Autophagy in Neurodegeneration
Neurodegenerative disorders are devastating, irreversible conditions that are
characterized by the loss of neurons in the brain. In many cases, the onset of
neurodegeneration associated with diseases including Parkinson’s and Alzheimer’s, is
sporadic with no known genetic or environmental cause [60,61]. Given the absence of a
causative agent, there are no disease-modifying treatments available, and existing drugs
serve only to treat symptoms in an attempt to prolong the effects of disease progression
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[62]. There exits an important need for treatment options that prevent, slow or stop the
progression of neurodegenerative disorders.
Neurodegenerative disorders can affect different areas of the nervous system, and
cause patients to exhibit different symptoms depending on the disease; however, many
share important characteristics outside the gradual loss of neurons over time. For
example, Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis and
Huntington’s Disease all exhibit protein aggregate pathology in the form of
neurofibrillary tangles, Lewy bodies, inclusion bodies, and mutant huntingtin aggregates,
respectively [63]. It is believed that these aggregates are toxic and play a role in neuronal
death. Neurodegenerative disorders are also commonly associated with aberrant
activation of the innate and adaptive immune systems in the central nervous system.
Currently, significant research efforts are focused on targeting the mechanism by which
these aggregates are removed by cell, namely autophagy. Alternatively, efforts also
include studying the role inflammation plays in these disorders [64].
Autophagy is a cellular process responsible for maintaining protein homeostasis
in the cell. While there is more than one mechanism of autophagy, macro-autophagy is
the most studied and best understood type. For this reason, we will focus on macroautophagy (hereafter referred to as autophagy). In autophagy, cytoplasmic materials such
as proteins, metabolites, and organelles are engulfed by membrane-bound vesicles known
as autophagosomes. These autophagosomes are then trafficked to a lysosome, which then
fuses with the autophagosome and is then degraded and released [63].
Because a hallmark of neurodegenerative diseases is the accumulation of protein
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aggregates, and autophagy is known to clear large aggregates of protein, autophagy is
thought to be a potential target for a disease-modifying treatment. Furthermore,
dysfunction in autophagy and its regulation have been implicated in many common
neurodegenerative diseases. In Parkinson’s Disease, mutations in PTEN-Induced Kinase
1 (PINK1) and Parkin, an E3 ubiquitin ligase involved in mitochondrial turnover, are
known to disrupt the autophagic degradation of mitochondria leading to stress-induced
mitochondrial dysfunction and cell death. Additionally, mutations in Park9 disrupt
acidification in the lysosome [65]. In AD, reductions in expression of Beclin 1, a protein
involved in the induction of autophagy, and Rab5, an endosomal and lysosomal regulator,
have been implicated in the progression of the disease [65]. Finally, in Huntington’s
disease, huntingtin protein is involved in various aspects of autophagy, such as cargo
recognition, endosomal and lysosomal regulation, and vesicular trafficking, and its
canonical polyglutamine tract mutation has been shown to interfere with these regular
functions (of autophagy) (Figure B4) [65]. Felodipine and lonafarnib are two examples
of drug repurposing candidates that have undergone study for their activity to target
autophagy.
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Figure B4. Autophagy mechanism and associated gene dysfunctions. Autophagy
is a cellular mechanism by which metabolites, organelles, proteins and protein
aggregates are enveloped by a vesicular membrane to form an autophagosome. This
autophagosome is trafficked to a lysosome where fusion occurs, and lysosomal
degradative enzymes break down the cargo. Dysfunction in several genes associated
with neurodegenerative diseases have been implicated and are known to disrupt
autophagy. Figure 4 image created using BioRender.com.
Felodipine
Felodipine is an antihypertensive drug originally approved by the FDA in 1988
[66]. It prevents hypertension by inhibiting L-type calcium channels and preventing
calcium-dependent smooth muscle contractions, namely those responsible for
constriction of the blood vessels [66] Currently, it is being investigated as an inducer of
autophagy in Huntington’s Disease and Parkinson’s Disease models.
Calcium influx inhibition induces autophagy by reducing the activity of calciumdependent cysteine proteases, which are also known as calpains. Upon activation,
calpains cleave G-proteins, which results in the activation of adenylyl cyclase. Activated
adenylyl cyclase increases the amount of cyclic AMP (cAMP) in the cell and activates
phospholipase C. Phospholipase C is responsible for the generation of
phosphatidylinositol 3-phosphate (PIP3), which is a direct inhibitor of autophagy and
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allows more calcium to enter the cell creating a positive feedback loop. By blocking
cytoplasmic calcium, there is a net reduction in PIP3 and an induction of autophagy [67].
Felodipine activity to induce autophagy by blocking L-type calcium channels was
identified as favorable in a screen of drugs assessed in primary mice neurons [68] Out of
nine calcium channel blockers, felodipine showed the greatest increase in
autophagosomes and autophagolysosomes. The efficacy of felodipine has been further
assessed in zebrafish models of tauopathy, a class of neurodegenerative disease involving
the aggregation of Tau protein in the human brain, mouse models of Huntington’s
Disease, and mouse models of Parkinson’s Disease [68]. In mice, felodipine has the
ability to ameliorate signs of Huntington’s disease over a treatment period of 12 weeks
and resulted in improved clearance of alpha-synuclein, the main component of Lewy
bodies. Twenty-two B6HD mice, a Huntington’s Disease model, were treated with
felodipine starting in their sixth week from birth, and were tested for grip strength, wire
maneuvering and tremors, every two weeks from age 7 to 19 weeks. Felodipine treated
mice were reported to have better grip strength from week 11-19 and a reduction in
tremors from weeks 17-19, when compared to vehicle-treated control mice [68].
Likewise, A53T alpha-synuclein mice, a common Parkinson’s Disease mouse model,
were shown to have improved grip strength, increased neuron numbers in the substantia
nigra (the area of the brain affected by Parkinson’s Disease), and a reduction in insoluble
alpha-synuclein, a protein that comprises Lewy bodies. In zebrafish, a rho: tau model was
used to emulate cell death associated with the aggregation of Tau protein commonly
associated with Alzheimer’s Disease. In this model, wild-type human tau protein is
expressed in rod photoreceptors and causes cell death. Felodipine successfully rescued
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rod cell death, but failed to do so in zebra fish lacking atg7, a vital autophagy gene,
suggesting the effect of felodipine on these cells is dependent on autophagy [68].
While felodipine has shown promise as a potential new treatment for
neurodegeneration, cautious skepticism is advised due to how recent the studies have
been conducted and the scope of studies has been limited to preclinical models of disease.
Human clinical trials and efficacious dosage regimens remain to be conducted. Due to
differences between human and mouse physiology, felodipine is metabolized much
quicker in mice. As a result, the mice in this study were exposed to transient exposures of
felodipine that are two orders of magnitude higher than the dosage indicated for use as an
antihypertensive drug in humans. It is possible that the required dosage is so high that
deleterious side-effects may preclude human treatment. Finally, the models used in this
work were only successful in showing that felodipine can clear protein aggregates; the
studies did not include the full disease course or its progression.
Lonafarnib
Lonafarnib is a promising drug that has passed phase two clinical trials for the
treatment of progeria, a genetic disorder causing accelerated aging in children, and phase
three clinical trials for the treatment of hepatitis delta virus infections [69]. Lonafarnib is
a farnesyltransferase inhibitor that prevents prenylation, the addition of a lipid group to
the cysteine residues of proteins. In hepatitis delta infections, prenylation is required for
the assembly and packaging of new viral particles.68 By inhibiting prenylation, fewer
viral particles are created. In progeria, a genetic mutation causes Lamin A to be truncated
and form progerin. Lamin A is an important part of the nuclear membrane structure and
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may be required for the repair of double-stranded DNA breaks [70]. When progerin, is
formed instead, it is prenylated and cannot incorporate into the nuclear membrane. By
inhibiting farnesyltransferase and prenylation, the instability of the nuclear membrane
can be rescued [70].
Interestingly, lonafarnib shows promise as an inducer of autophagy and may be a
possible therapeutic to treat tauopathy. In the cell, autophagy is regulated by the
mechanistic target of rapamycin (mTOR) kinase, also commonly referred to as FK506binding protein 12-rapamycin-associated protein 1 (FRAP1). When mTOR is active,
autophagy is inhibited. mTOR itself is regulated by the G-protein, Rheb, which is
functional when localized to the cell membrane via a fatty acid chain tether.
Farnesyltransferase inhibitors, such as lonafarnib disrupt the prenylation of Rheb and
prevent its localization to the inner cell membrane. Without Rheb in the proper position,
mTOR cannot be activated, resulting in an upregulation of autophagy [71].
Lonafarnib has been shown to induce autophagy in primary mice fibroblast cells
as well as improving symptoms in mice models of dementia. In a study by Hernandez et
al., transgenic NIH3T3 mouse fibroblast cells were used to show efficacy in inducing
autophagy [72]. NIH3T3 cells were used to perform a fluorescent assay that can
determine the rate of autophagy[71]. NIH3T3 cells treated with increasing doses of
lonafarnib exhibited dose-dependent increases in autophagolysosomes suggesting a
lonafarnib mediated increase in autophagy. Furthermore, Tg4510 mice, used as a
dementia model displaying behavioral impairments associated with dementia, were
treated with lonafarnib starting at 10 weeks of age. At 20 weeks, mice were assessed for
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nest building behaviors. Treated mice displayed an improvement in nest shredding, a trait
associated with these mice. Lonafarnib was also able to ameliorate the circling behavior
attributed to this model, but not reverse it after already manifesting. Due to these
findings, it was concluded that lonafarnib cannot reverse existing tau pathology, but can
prevent it from worsening [72].
While lonafarnib is indeed a promising drug, it is important to consider that this
drug is still in relatively early stages of the drug discovery pipeline. It has not yet been
approved by the FDA and is not clinically available. It is also important to note that the
successful use of this drug as a treatment for dementia would also be hindered by the fact
that lonafarnib cannot reverse the damage done by tauopathy. Because of this, lonafarnib
may be essential in patients with early diagnoses. Studies on the inhibition of prenylation
of proteins should be performed to determine if lonafarnib may have any off-target
effects, as there are many proteins that need to be prenylated to function correctly. It is
likely that in the case of progeria, the life-saving effect seen by long term use of this drug
outweighs any potentially harmful side-effects, but the same cannot be inferred for
dementia.
Inflammation and NRF2 as a Target in Neurodegeneration
Chronic inflammation in the brain is associated with many neurodegenerative
disorders including psoriasis, multiple sclerosis, Parkinson’s disease, macular
degeneration, cutaneous T-cell lymphoma, obstructive sleep apnea, adult brain
glioblastoma and rheumatoid arthritis [64]. It is believed that the innate immune response
and chronic inflammation of the brain mediated by microglia and astrocytes have a role
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in the onset of neurodegeneration, and there is interest in studying therapeutics to reduce
neuroinflammation. As an example, nuclear factor (erythroid derived 2)-like2 (NRF2) is
a transcription factor that regulates the expression of detoxifying enzymes and
antioxidant genes including NAD(P)H quinone oxidoreductase 1, heme oxygenase1(HO-1), glutathione S-transferase (GST) genes, and UDP-glucuronosyltransferase
(UGT) genes. NRF2 is inhibited by KEAP1 under normal conditions, but NRF2 is
activated under stressful conditions. Under normal conditions, KEAP1 binds to NRF2
and mediates its degradation via the ubiquitin-proteasome system. However, under
conditions of oxidative stress, KEAP1 releases NRF2 allowing it to upregulate any
number of antioxidant genes. One such gene is HO-1. HO-1 catalyzes the degradation of
heme into carbon monoxide (CO), free iron, and biliverdin as well as directly
upregulating anti-inflammatory cytokines and inhibiting pro-inflammatory cytokines. In
addition to these points, CO inhibits NFκB, a signaling protein responsible for promoting
pro-inflammatory cytokines [73]. Activation of the NRF2 signaling pathway, which is
shown in (Figure B5), has a net anti-inflammatory effect. Dimethyl fumarate and
exemestane are two drugs that could be repurposed for treatment of inflammation due to
aberrant NRF2 signaling pathway.
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Figure B5. NRF2 signaling and inflammation. Under basal conditions, NRF2 is
bound to its repressor, KEAP1 and ultimately degraded by the proteasome
following ubiquination. However, under oxidative stress, free NRF2 translocates to
the nucleus and dimerizes with small MAF family proteins. This complex binds to
and promotes the expression of genes with an antioxidant response element, such as
HO-1. HO-1 directly inhibits pro-inflammatory cytokines while upregulating antiinflammatory cytokines as well as catalyzing the breakdown of heme into carbon
monoxide, free iron, and biliverdin. Carbon monoxide is an inhibitor of the NFκB
pathway, resulting in an overall decrease of pro-inflammatory cytokines. The figure
B5 image was created using BioRender.com.
Dimethyl Fumarate
Fumaric acid derivatives were first utilized in the 1950’s for the treatment of
psoriasis. The hypothesized mechanism of action for fumaric acid and its derivatives was
thought to be that a combination of oral and topical administration of these compounds
restored an imbalance in the citric acid cycle, as fumaric acid is an intermediate product
in the cycle, and a fumarate deficiency was proposed as a problem in patients with
psoriasis [74]. However, early clinical trials could not reproduce these results and
fumarates were discontinued for over ten years. In the early 1990s, the first clinical trial
for dimethyl fumarate (DMF) was conducted for the treatment of psoriasis and the results
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proved favorable in regards to severe plaque psoriasis [75]. The topical, exogenous
administration of dimethyl fumarate (Figure B6), also known as Fumaderm®, evolved
over time into an oral formulation in the late 1990’s. Germany licensed Fumaderm® as
an oral treatment for moderate to severe psoriasis[76].

Figure B6.

The structure for dimethyl fumarate.

DMF was approved by the FDA in 2014 under the trade name Tecfidera® as a
medication to treat relapsing forms of multiple sclerosis (MS) [77,78]. Multiple sclerosis
is an autoimmune disease in which the myelin sheath surrounding nerves is attacked and
degrades, resulting in pain and motor function impairment. DMF is metabolized to
monomethyl fumarate when administered to a patient. Monomethyl fumarate acts as an
agonist of the nAChR, resulting in activation of the NRF2 pathway, which leads to a
reduction in the inflammation that exacerbates demyelination. More recently, DMF has
been found to activate this same anti-inflammatory pathway in Parkinson’s disease
patients, providing a promising treatment option for neurodegeneration that appears to
work in mouse models of α-synucleinopathy [79]. In PD, DMF has demonstrated a
neuroprotective effect by ameliorating mitochondrial dysfunction and upregulating
mitochondrial biogenesis by blocking neurotoxicity in wild-type, but not Nrf2 knockout
mice [80].
On par with other immunomodulation treatments, DMF does not have a singular
mechanism of action or one biochemical pathway that is targeted with administration.
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Rather, it is believed that DMF has multiple targets and exerts a spectrum of biological
effect that leads to the therapeutic action of DMF experienced by MS patients. As shown
in in vitro studies, DMF partially exerts anti-inflammatory action with the ability to
increase the production of interleukin-4 (IL-4) and IL-5 when added to cultures of
stimulated peripheral mononuclear blood cells. These cytokines are conducive to
producing and promoting a Th2 immune response. The perturbation away from the Th1
response was also replicated in dendritic cells. The polarization of the immune response
away from Th1 and toward the Th2 profile is a probable mechanism for DMF function as
an immunomodulator. There is also evidence that DMF stimulates the native antioxidative stress machinery in cells. The anti-oxidative response is activated by NRF2, the
primary transcription factor for genes associated with the anti-oxidative response. DMF
has been shown to enhance the nuclear translocation of NRF2, and thus activating
transcription of associated genes. The effect DMF has on the NRF2 pathway is likely a
profound contributor to the mechanism of action [77].
In a study by Lastres-Becker et al., rAAV6-ɑ-synuclein NRF2+/+ and NRF2-/mice were treated with DMF for 1 and 3 weeks followed by additional treatments every
other day for eight weeks [79]. One day before sacrifice, the mice were assessed for
motor asymmetry via the elevated body swing test. The NRF2-/- mice displayed
significantly increased contralateral body torsion compared to the NRF2+/+ mice [81].
Additionally, DMF was assessed for its effect on signs of inflammation at the tissue level.
One sign of inflammation in Parkinson’s Disease is the increase of microglia and
astrocytes in the basal ganglia known as microgliosis and astrocytosis, respectively. In
order to test the effect of DMF on these inflammatory markers, NRF2+/+ mice treated
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with DMF displayed significant decreases in astrocytosis and microgliosis compared to
the NRF2-/- mice. In the brain, microglia can express one of two phenotypes, a proinflammatory, IL-1β and inducible nitric oxide synthase (iNOS)-producing phenotype
and anti-inflammatory, IL-4 and sphingosine kinase 2-producing phenotype. DMF was
shown to mediate the conversion of the pro-inflammatory phenotype to the antiinflammatory phenotype in mouse BV2 microglial cells. Cells treated with DMF
displayed increased levels of IL-4 mRNA in a time-dependent manner [79]. DMF was
also shown to have a neuroprotective effect on BV2 cells in studies where the cells were
pretreated with DMF and then exposed to ɑ-synuclein. Untreated cells had an induction
of IL-1β and iNOS whereas pretreated cells displayed lower pro-inflammatory marker
induction. Based on these findings, NRF2 appears to be a potentially useful target for
Parkinson’s Disease treatment, and DMF may bring us one step closer to a disease
modifying drug [81].
A survey of clinical trial data yielded that DMF has been or is being investigated
for efficacy in treating the following disease states: Primary Progressive Multiple
Sclerosis, Relapsing-Remitting Multiple Sclerosis, Age-related Macular Degeneration,
Cutaneous T Cell Lymphoma, Obstructive Sleep Apnea, Adult Brain Glioblastoma and
Rheumatoid Arthritis. While there is a diversity of pathologies being investigated with
the administration of DMF, inflammation arises as a shared theme in these clinical trials.
Immunomodulation, down regulation of proinflammatory cytokines, the effect of DMF
on T cell regulation, and DMF exerts in vitro could be of utility in treating a myriad of
diseases [82–84].
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Exemestane
Exemestane was approved by the FDA in 1999 and is marketed as Aromasin, an
aromatase inhibitor for use on estrogen-dependent breast cancers, especially in postmenopausal women [85,86]. Exemestane treats breast cancer by preventing the synthesis
of estrogen via the inhibition of the aromatization step of androgens into estradiol, a
precursor of estrogen. Without estrogen, these estrogen-dependent cancers’ growth and
spread is inhibited. Exemestane was identified as a potential treatment for Parkinson’s
Disease through a screen aiming to find compounds that activate HO-1 [87]. Exemestane
was found to be one of the most effective compounds in the screen. The proposed
mechanism for treating Parkinson’s Disease is different than that of treating breast
cancer, where aromasin inhibits the formation of estrogen from androgen during the ratelimiting step of aromatase conversion [88,89]. In this sense, aromasin acts as an
upregulator of NRF2 expression, a transcription factor responsible for producing antioxidant enzymes in order to circumvent the degeneration of dopaminergic neurons due to
high amounts of oxidative stress from ROS such as NO [85,90].
In a study by Son et al, (2017), exemestane was validated in BV2 microglial cells
and in MPTP mouse models of Parkinson’s Disease. BV2 cells were tested for NRF2
protein levels, HO-1 and NQO1 mRNA levels, and iNOS and IL-1β levels following
exemestane treatment.85 NRF2 expression was elevated, suggesting exemestanemediated activation. Likewise, the expression of NRF2 downstream genes increased with
exemestane treatment, while inflammatory marker levels decreased. Taken together,
these results signify a possible reduction of inflammation by exemestane. In the same
study, exemestane was also evaluated in a mouse model of Parkinson’s Disease. Mice

144
were treated with MPTP, a neurotoxin that kills dopaminergic neurons and attempts to
simulate the death of neurons in Parkinson’s Disease. The mice were then coadministered with exemestane orally (10 mg/kg) three times a day every day for seven
days. Following treatment, the mice were sacrificed. Immunostaining was performed for
tyrosine hydroxylase, a selective marker expressed by dopaminergic neurons. Mice cotreated with exemestane exhibited a reduction in the loss of dopaminergic neurons caused
by MPTP [85].
DMF and exemestane both show enticing results as potential new treatments for
Parkinson’s Disease; however, the exact molecular target of either drug remains
unknown. The Parkinson’s Disease model studies performed with DMF and exemestane
are still preclinical, limiting any interpretation of results regarding potential efficacy in
humans. One concern that may be raised for exemestane experiments has to do with the
MPTP mouse model. The addition of a toxin does not necessarily recapitulate
Parkinson’s Disease progression because the neurons die all at once instead of gradually
over time as they would in human disease progression. Additionally, the results from the
Son et al study seem to contradict previous reports that estradiol has a neuroprotective
effect in PD [16]. However, estradiol and its inhibitor, exemestane, exhibit their
neuroprotective qualities through separate pathways- JNK and NRF2, respectively. This
would necessitate further studies on the effects of estradiol and its inhibition in the
context of PD. Another consideration that must be made is that the experiments
conducted on mice for both drugs were done over a relatively short period of time. The
DMF treatments lasted eight weeks and the exemestane tests were done for seven days. It
will be necessary to discover how long-term treatments affect the progression of
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Parkinson’s Disease in more relevant model systems up to and including human trials.
Conclusion
The benefit of repurposing drugs that have previously been FDA approved removes
many of the time and financial barriers for bringing a drug to market. FDA approval is a
good indication of a drug’s effectiveness and safety in clinical trials, which is indicative
of a good outcome for the use of a drug for a different purpose. Because a drug can take
anywhere from 8-12 years to go from initial discovery to the market, drug repurposing
can cut this time significantly[1]. The repurposing of drugs to treat cardiovascular and
neurodegenerative diseases is an emerging and promising field of study. Treatments for
inflammatory diseases including vascular endothelial dysfunction, pulmonary arterial
hypertension, multiple sclerosis, Parkinson’s,and Alzheimer’s, using repurposed drugs
like colchicine, methotrexate, tocilizumab, felodipine, lonafarnib, dimethyl fumarate and
exemestane may prove to be an effective strategy to address the treatment gap for
untreatable ailments
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